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Abstract/Zusammenfassung 
Abstract 
One of the most important classes of membrane proteins are G-Protein-coupled-receptors 
(GPCRs). GPCRs represent a big part of the protein coding genome and are responsible for 
many biochemical processes, ranging from cancer to neurology. Due to their big role in 
physiology and pathophysiology, many drugs target GPCRs, to date approximately 1/3 of all 
FDA approved drugs. In order to understand these processes better and to develop drugs 
targeting those signaling pathways, it is from biggest importance to get a deeper 
understanding of the structure and dynamics of GPCRs and their corresponding G-proteins. 
In this work, I used evolutionary stabilized Neurotensin 1 Receptor (NTR1) variants with 
different signaling capacity as a model system for the investigating the dynamics and 
interactions of a GPCR by NMR spectroscopy. The reason for this choice is an easy and 
effective production of this GPCR in E. coli, which is needed for isotope labeling for nuclear 
magnetic resonance (NMR) spectroscopy experiments. On the G-protein side, either the 
heterotrimeric G-protein extracted from insect cells or the alpha subunit (Gα) produced in 
E.coli was used. The key goal was to understand the effects of the dynamics of GPCRs and G-
proteins on their interaction with each other. 
The first goal was to study the role of the nucleotide state of Gα on its structure and dynamics 
and therefor on its interaction with an activated GPCR. Thereby I showed that Gα in an apo 
state has the highest affinity to an activated GPCR as well as an open conformation enhancing 
GTP binding. In line with these findings, GTP-bound Gα shows no significant affinity to an 
activated GPCR with a tightly closed conformation. I used NMR experiments for the 
investigation of labeled Gα in this project. The second part of my work was focused on the 
GPCR side. Therefore, different labeling strategies like 13C methyl sulfide or selective 
isoleucine, leucine, valine and alanine (ILVA) labeling were used in order to facilitate NMR 
experiments to detect allosteric structural changes and dynamics during signaling. I could 
show that GPCR activation affects the whole GPCR with an allosteric mechanism, resulting 
in a helix 6 rearrangement on the cytosolic side. This is essential for the interaction of a GPCR 
with G-proteins. Furthermore, I could verify the importance of the ionic lock motif GPCR 
signaling.  
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In summary, I was able to obtain a deeper understanding of the interaction between GPCRs 
and G-proteins, with a focus on each binding partner. Nonetheless, future experiments are 
required to further characterize GPCR plasticity and determine the allosteric structural 
changes that are required to transfer the signal induced by ligand binding through the 
membrane to activate a bound G-protein.    
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Zusammenfassung 
Eine der wichtigsten Klassen von Membranproteinen sind G-Protein-gekoppelte Rezeptoren 
(GPCRs). GPCRs stellen einen großen Teil des Protein-kodierenden Genoms dar und sind für 
viele biochemische Prozesse verantwortlich, die von Krebs bis zur Neurologie reichen. 
Aufgrund ihrer großen Rolle in der Physiologie und Pathophysiologie zielen viele 
Medikamente auf GPCRs ab, bis heute etwa 1/3 aller von der FDA zugelassenen Medikamente. 
Um diese Prozesse besser zu verstehen und Medikamente zu entwickeln, die auf diese 
Signalwege abzielen, ist es von größter Bedeutung, ein tieferes Verständnis der Struktur und 
Dynamik von GPCRs und ihren entsprechenden G-Proteinen zu erlangen. 
In dieser Arbeit verwendete ich evolutionär stabilisierte Neurotensin-1-Rezeptor (NTR1) -
Varianten mit unterschiedlicher Signalkapazität als Modellsystem für die Untersuchung der 
Dynamik und Wechselwirkungen eines GPCR mittels NMR-Spektroskopie. Der Grund für 
diese Wahl ist eine einfache und effektive Herstellung dieses GPCR in E. coli, die für die 
Isotopenmarkierung für Kernspinresonanz (nuclear magnetic resonance, NMR) – Spektro-
skopieexperimente benötigt wird. Auf der G-Protein-Seite wurde entweder das aus 
Insektenzellen extrahierte heterotrimere G-Protein oder die in E. coli hergestellte Alpha-
Untereinheit (Gα) verwendet. Das Hauptziel war es, die Auswirkungen der Dynamik von 
GPCRs und G-Proteinen auf ihre Wechselwirkung miteinander zu verstehen. 
Das erste Ziel war es, die Rolle des Nukleotidzustands von Gα auf seine Struktur und Dynamik 
und damit auf seine Wechselwirkung mit einem aktivierten GPCR zu untersuchen. Dabei 
habe ich gezeigt, dass Gα in einem Apo-Zustand die höchste Affinität zu einem aktivierten 
GPCR sowie eine offene Konformation aufweist, die die GTP-Bindung verstärkt. In 
Übereinstimmung mit diesen Befunden zeigt GTP-gebundenes Gα keine signifikante Affinität 
zu einem aktivierten GPCR mit einer eng geschlossenen Konformation. Ich habe in diesem 
Projekt NMR-Experimente zur Untersuchung von markiertem Gα verwendet. Der zweite Teil 
meiner Arbeit konzentrierte sich auf die GPCR-Seite. Daher wurden verschiedene 
Markierungsstrategien wie 13C-Methylsulfid oder selektive Isoleucin-, Leucin-, Valin- und 
Alanin-Markierung (ILVA) verwendet, um NMR-Experimente zum Nachweis allosterischer 
Strukturänderungen und -dynamiken während der Signalübertragung zu erleichtern. Ich 
konnte zeigen, dass die GPCR-Aktivierung den gesamten GPCR mit einem allosterischen 
Mechanismus beeinflusst, was zu einer Helix-6-Umlagerung auf der zytosolischen Seite führt. 
Dies ist wesentlich für die Wechselwirkung eines GPCR mit G-Proteinen. Darüber hinaus 
konnte ich die Bedeutung des „ionic lock“ Motivs bestätigen für die GPCR-Signalübertragung. 
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Zusammenfassend konnte ich ein tieferes Verständnis der Wechselwirkung zwischen GPCRs 
und G-Proteinen gewinnen, wobei ich mich auf jeden Bindungspartner konzentrierte. 
Dennoch sind zukünftige Experimente erforderlich, um die GPCR-Plastizität weiter zu 
charakterisieren und die allosterischen Strukturänderungen zu bestimmen, die erforderlich 
sind, um das durch Ligandenbindung induzierte Signal durch die Membran zu übertragen und 
ein gebundenes G-Protein zu aktivieren. 
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1. Introduction 
1.1. G-Protein-coupled-receptors (GPCRs) 
G-Protein-coupled-receptors (GPCRs) play an important role in cell physiology. They are 
membrane proteins consisting of seven transmembrane (TM) α-helices. Due to their 
importance in human physiology, they represent an important drug target. So far, more than 
30 % of all drugs which have been approved by the US Food and Drug Administration (FDA) 
target GPCRs (Hauser et al., 2017; Wacker et al., 2017). These drugs are used to treat various 
diseases like cardiovascular diseases, inflammatory diseases or problems with the central 
nervous system (CNS). Still, only 27 % of all human non-olfactory GPCRs have been targeted 
so far (Santos et al., 2017). This number shows that there is still a lot of potential for the 
discovery of new drugs, treating GPCR-linked diseases. 
Generally activated GPCRs induce heterotrimeric G protein induced downstream signaling. 
There also exists G protein independent signaling pathways like β-Arrestin mediated 
downstream signaling (Peterson and Luttrell, 2017). As this thesis is focused on the structure 
and dynamics of GPCRs and G proteins, the attention will be directed to G protein dependent 
downstream signaling. Figure 1.1 shows a schematic overview of GPCR mediated signaling. 
 
Figure 1.1: G-protein-coupled receptor (GPCR) mediated signaling 
The GPCR signaling starts with agonist binding to the GPCR. Thereby the GPCR changes its conformation and is active. GDP 
bound heterotrimeric G protein is inactive, but has an increased affinity to bind active GPCRs (1). Upon binding between the 
activated GPCR and the G protein, a conformational change in the α subunit (especially helix 5 of the Ras domain) of the 
G protein enhances the dissociation of the GDP in the nucleotide binding pocket. This apo state of the G protein has the highest 
affinity to the activated GPCR and GTP (2). As soon as GTP binds to the α subunit of the G protein, the G protein dissociates 
from the activated GPCR. The two major subunits dissociate into the α subunit and the βγ subunit. Both are responsible for 
downstream signaling and have no significant affinity to the activated GPCR (3). When the α subunit hydrolyzes the GTP to 
GDP with its intrinsic enzymatic activity, the heterotrimeric G protein can reassemble and the cycle can start again. Figure 
shown as in the original publication (Goricanec et al., 2016). 
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In the Guanosine diphosphate (GDP) bound state, the G Protein α subunit forms a 
heterotrimer with the βγ subunit. This GDP bound heterotrimeric G Protein is signaling 
inactive. If a GPCR is activated by an agonist, the nucleotide exchange from GDP to 
Guanosine triphosphate (GTP) is catalyzed in the α subunit. This results in the dissociation 
of the heterotrimeric G protein (Oldham and Hamm, 2008). The GTP bound α subunit as well 
as the βγ subunit are both activating various effectors, i.e. adenylyl cyclase, Ca2+ channels, 
phospholipase C, cGMP (cyclic guanosine monophosphat) phosphodiesterase or phospho-
inosite 3 kinase (Khan et al., 2013; Milligan and Kostenis, 2006; Smrcka, 2008). As soon as GTP 
is hydrolyzed to GDP due to the intrinsic GTPase activity of the α subunit, the heterotrimer 
is formed again. This stops the signaling potency of both subunits and completes the GPCR 
G protein activation cycle. 
It was shown that certain receptors had in common that they catalyze the nucleotide 
exchange in heterotrimeric G proteins (Gilman, 1987). Over time, genome wide sequencing 
displayed that more than 800 such receptors can be classified as GPCRs (Fredriksson et al., 
2003). These GPCRs can then be divided in 5 different classes. The by far biggest class is the 
“rhodopsin-like” family (class A) consisting over 700 different members (Alexander et al., 
2017). It has receptors selective for biogenic amines, peptides, lipids, nucleotides and odorants 
to only name some ligand types. The “secretin-like” family (class B) usually binds long 
α-helical peptides like the glucagon receptor. The third family is the “adhesion-like” one. So 
far it is fairly little known about these receptors. The “glutamate-like” family (class D) has the 
glutamate receptor and γ-amino butyric acid (GABA) receptor as most known members. 
Finally, the least understood GPCR family is the “frizzled-like” (class F) which plays important 
roles in developmental biology. 
To improve the comparability of class A GPCRs, the “Ballesteros Weinstein nomenclature” 
was developed (Ballesteros and Weinstein, 1995). Thereby the most conserved residue in each 
transmembrane helix is given the number 50 and the number of the TM helix is put in front 
(i.e. R3.50 for the arginine of the ionic lock in helix 3). All other are residues numbered relative 
to this position. For each individual GPCR the position in the sequence can be added in 
brackets after the amino acid identifier (i.e. R3.50(167) in the case of the neurotensin 
receptor 1 (NTR1)). The chosen conserved residues as well as their relative position in the 
NTR1 are shown in Table 1.1. 
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Table 1.1. Generalized numbering scheme according to Ballesteros and Weinstein 1995 
Transmembrane helix 
(TMH) 
100% conserved in 
neurotransmitter GPCR 
AA 
identifier 
AA No. in 
rat NTR1 
AA identifier in 
rat NTR1 
1 Asn N1.50 82 N1.50(82) 
2 Asp D2.50 113 D2.50(113) 
3 Arg R3.50 167 R3.50(167) 
4 Trp W4.50 194 W4.50(194) 
5 Pro P5.50 249 P5.50(249) 
6 Pro P6.50 323 P6.50(323) 
7 Pro P7.50 366 P7.50(366) 
 
The first solved structure of a GPCR was bovine rhodopsin (Palczewski et al., 2000). It was 
extracted from cow retinas and it is the reference structure of an inactive class A GPCR as it 
shows no basal activity at all.  
The first GPCR for which a structure with a diffusible ligand was solved, was the beta-2 
adrenergic receptor (β2AR) with Carazolol, a high affinity inverse agonist. To enable the 
structure determination, β2AR had to be stabilized. This was done with two different 
approaches. One of the approaches for the structure determination was to use a Fab5 antibody 
fragment (Day et al., 2007) binding to the very flexible 3rd intracellular loop (IC3) to stabilize 
the Carazolol bound structure of β2AR in lipid bicelles (Rasmussen et al., 2007). The other 
approach was to genetically engineer a T4 lysozyme (T4L) into the GPCR which then replaces 
most of the IC3 of β2AR. With this construct, the structure of Carazolol bound β2AR in lipidic 
cubic phases was also solved (Cherezov et al., 2007). Both approaches were compared and 
showed a very similar structure (Rosenbaum et al., 2007). The latter study also compared the 
Carazolol bound β2AR structures to the structure of bovine rhodopsin. It was shown that the 
interaction in the ionic lock between the E(D)RY motif and the E6.30 is only present in the 
bovine rhodopsin, but not in the case of β2AR. This shows that Carazolol does not inhibit the 
basal activity of β2AR completely.  
These methods were also applied to other GPCRs and lead to structures being solved, i.e. the 
M3 muscarinic acetylcholine receptor with T4L fusion bound to the antagonist tiotropium 
(Kruse et al., 2012) or the δ-opioid receptor with T4L fusion bound to the antagonist 
naltrindole (Granier et al., 2012). All these structures showed the distinct features of class A 
GPCRs. 
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Experiments to solve agonist bound structures of GPCRs with the previously shown methods 
(either the T4L or the Fab) failed. This can be explained by lower stability of the active state 
of a GPCR in the absence of a G protein. In order to stabilize these GPCRs in their active state, 
nanobodies can be designed which show a G protein-like behavior (Manglik et al., 2017; 
Steyaert and Kobilka, 2011). For β2AR a screening showed that Nb80 behaves like a G protein 
and therefor was used to obtain the active structure (Rasmussen et al., 2011a). In this study 
BI-167107 was used as agonist, as it showed better efficacy, affinity and off-rate profile than 
isoproterenol. 
This method has led to many solved active-state GPCR structures. In the case of β2AR it was 
also possible to compare multiple different agonists and their effect on the structure (Ring et 
al., 2013). Other examples for known structures of GPCRs in an active state are the M2 
muscarinic acetylcholine receptor (Kruse et al., 2013) and µ-opioid receptor (Huang et al., 
2015). 
Most GPCRs have a basal signaling activity, which can be influenced by ligands. Ligands can 
be defined according to their influence on the signaling: a full agonist promotes maximum 
signaling, a partial agonist leads to submaximum signaling, an inverse agonist causes reduced 
basal activity whereas a neutral antagonist has no influence on the basal activity but 
competitively binds to the receptor (see Figure 1.2). 
 
Figure 1.2: Influence of various ligand types on receptor signaling 
This figure shows exemplary signaling activities of various different ligands on receptors. The apo or antagonist state represents 
the basal state. This should not be misunderstood as the state with the lowest activity. Inverse agonists decrease the signaling 
activity even further than the activity of the basal state. Full agonists maximize the signaling activity. Partial agonists can be 
anywhere between full agonists and the apo/antagonist state. This one showed in the figure is only randomly chosen for a better 
representation. 
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Ligands can also be differentiated depending on the selectivity of downstream signaling they 
promote (i.e. which G protein is favored or if there is a preference for G protein or β-Arrestin 
signaling). If any type of selectivity exists, the ligands causing it are called biased ligands 
(Kenakin, 2013; Smith et al., 2018). 
The way how ligands influence GPCR signaling is by stabilizing certain populations of the 
receptor. This phenomenon is called the conformational selection. Thereby the signal 
intensity (Ye et al., 2016) as well as the signal bias (Liu et al., 2012) are influenced. 
Ligand bias plays an important role in GPCR drug discovery as many side effects of drugs are 
caused by certain downstream signaling pathways which are not necessarily the same as for 
the desired effect of the drug (Kenakin, 2011; Smith et al., 2018). A prominent example for this 
in the case of GPCRs are opioid receptors, as they are one of the most drugged targets 
worldwide with severe problems caused by the side effects of the available drugs. It was 
shown that in the case of the µ-OR G protein biased ligands show fewer side effects than 
β-arrestin biased ligands (Majumdar and Devi, 2018; Manglik et al., 2016; Soergel et al., 2014). 
To better understand, how ligands alter GPCR dynamics and therefor select certain 
conformations, various class A GPCRs were compared. Thereby the most conserved sequence 
motifs were compared in the active and inactive state. As an exemplary GPCR, the β2-AR has 
been described in this context (Weis and Kobilka, 2018). 
One of the most conserved sequences is the D(E)3.49-R3.50-Y3.51 motif, which is present near 
the cytosolic side and close to the G protein binding site. If the GPCR is not active, the R3.50 
is stabilized by an intrahelical salt bridge to D(E)3.49 and additionally by interhelical 
hydrophobic interactions with L6.34 and L6.37. R3.50 also interacts with E6.30 and forms a 
salt bridge in dark rhodopsin. This motif is also called the ionic lock (Ballesteros et al., 2001). 
In most inactive GPCRs, this interactions form only transiently (Dror et al., 2009), which also 
explains a low basal activity for these GPCRs. 
As mentioned earlier, this work focuses on G proteins as effector molecules activated by 
GPCRs. Compared to the big diversity in GPCRs, heterotrimeric G proteins show only a small 
variety in the human genome. Based on their genetic homology, the human α subunit of G 
proteins (Gα) consists of 16 different genes which can be organized into 4 G protein families 
(Gαs, Gαi/o, Gαq/11 and Gα12/13). The human βγ subunit (Gβγ) is composed of 5 different β 
genes and 12 different γ genes (Downes and Gautam, 1999). Due to the big difference in the 
diversity of GPCRs and G proteins, it is assumed, that there is a conserved mechanism of 
GPCR mediated G protein acitivation. 
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The nucleotide binding site is between the two domains of Gα, the Ras-like (Ras) GTPase 
domain and the α-helical domain (AHD) (Oldham and Hamm, 2006; Sprang, 1997). Most 
interactions between the nucleotide and the Gα are present between the Ras domain and the 
nucleotide. The second part of the binding pocket is built by the AHD. Various biophysical 
studies have indicated that domain separation in Gα plays an important role in nucleotide 
release (Dror et al., 2015; Van Eps et al., 2011; Yao et al., 2016). Nevertheless, it also has been 
shown by deletion of the AHD, that even in the absence of the AHD, GDP still binds to the 
Ras domain and can activate downstream signaling (Markby et al., 1993). This finding is 
further supported by molecular dynamics (MD) simulations and double electron-electron 
resonance (DEER) distance measurements of GDP-bound heterotrimeric G proteins, showing 
even in case of domain separation or AHD deletion, that the nucleotide was still bound to the 
Ras domain (Dror et al., 2015). All these findings lead to the assumption that nucleotide release 
needs to be stimulated in the Ras domain via an activated receptor. 
As described earlier, many structures of inactivated as well as activated GPCRs haven been 
solved in recent years. In order to obtain a better understanding of GPCR signaling and 
dynamics, it was tried to obtain a structure of a GPCR and a G protein in complex. So far this 
only succeeded once via crystallography with a heterotrimeric G protein in complex with 
β2AR T4L and a G protein stabilizing nanobody (Rasmussen et al., 2011b). This structure also 
shows that the AHD of GDP-bound Gα flips out after binding to an activated GPCR. It was 
also the first structure showing the interactions between the cytoplasmic GPCR side and the 
G protein. Especially helix 5 (α5) of the nucleotide free Gα shows strong interactions with 
intracellular GPCR surface and displacement compared to GTP-bound Gα. Compared to the 
activated structure which has been only stabilized with a nanobody (Rasmussen et al., 2011a), 
the differences are neglectable. A common feature in activated class A GPCRs is the outward 
movement of TM6 (Latorraca et al., 2017) making it accessible to the G protein. The 
importance of TM6 movement for the interaction with the G protein is further supported by 
a comparison of 5 different class A GPCRs in their active as well as inactive state 
(Venkatakrishnan et al., 2016). 
Another advance in the investigation of GPCR G protein interaction was the use of optimized 
Ras domains, also called mini-G proteins (Carpenter and Tate, 2016; Nehme et al., 2017), 
instead of full length Gα to crystalize the complexes. When comparing the β2AR Gs structure 
(Rasmussen et al., 2011b) with A2AR in complex with a mini-Gs many similarities in the 
binding interface could be determined (Carpenter et al., 2016).  
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The most recent breakthrough in the structure determination of GPCR G protein complexes 
is the emerging of high resolution cryo electron microscopy (cryo-EM). The first solved 
cryo-EM structure of a GPCR in complex with a heterotrimeric G protein was the calcitonin 
receptor (Liang et al., 2017), shortly followed by the glucagon-like peptide-1 receptor (Zhang 
et al., 2017). Since then the structure of many GPCRs from different families in complex with 
heterotrimeric G proteins have been solved (see Table 1.2). 
 Table 1.2. Cryo-EM structures of different GPCRs in complex with heterotrimeric G proteins 
Receptor 
GPCR  
class 
G protein Res. Reference 
Calcitonin receptor (CALCR) B1 Gs 4.1 Å (Liang et al., 2017) 
Glucagon like peptide 1 
receptor (GLP1R) 
B1 Gs 4.1 Å (Zhang et al., 2017) 
Adenosine receptor A2a 
(A2AR) 
A Gs 4.1 Å (Garcia-Nafria et al., 2018a) 
µ-opioid receptor (µ-OR) A Gi/o 3.5 Å (Koehl et al., 2018) 
Serotinin receptor 1B 
(5-HT1BR) 
A Gi/o 3.8 Å (Garcia-Nafria et al., 2018b) 
Adenosine receptor A1 (A1R) A Gi/o 3.6 Å (Draper-Joyce et al., 2018) 
Rhodopsin A Gi/o 4.5 Å (Kang et al., 2018) 
Cannabinoid receptor 1 
(CNR1) 
A Gi/o 3.0 Å (Krishna Kumar et al., 2019) 
Parathyroid hormone 1 
receptor (PTH1R) 
B1 Gs 3.0 Å (Zhao et al., 2019) 
Muscarinic acetylcholine 
receptor M2 (CHRM2) 
A Gi/o 3.6 Å (Maeda et al., 2019) 
Muscarinic acetylcholine 
receptor M1 (CHRM1) 
A Gq/11 3.3 Å (Maeda et al., 2019) 
Smoothened F Gi/o 3.9 Å (Qi et al., 2019) 
Neurotensin receptor 1 
(NTR1) 
A Gi/o 3.0 Å (Kato et al., 2019) 
 
1.2. Neurotensin Receptor 1 (NTR1) 
The Neurotensin receptor 1 (NTR1) is a class A GPCR involved in many physiological 
processes, i.e. cancer (Wu et al., 2012), central nervous system (CNS) disorders (Boules et al., 
2013) or diabetes (Mustain et al., 2011). Therefor NTR1 is a promising drug target with big 
therapeutic potential (Kitabgi, 2002). The natural agonist for the NTR1 is Neurotensin (NTS), 
a 13 amino-acid peptide ligand (ELYENKPRRPYIL), being a neurotransmitter in the CNS as 
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well as a hormone in the periphery, especially the digestive tract (Vincent et al., 1999). NTR1 
preferably interacts with Gq, but is also capable to promote downstream signaling via all other 
G protein families (Besserer-Offroy et al., 2017). Various structures of the rat NTR1 bound to 
NTS8-13 (RRPYIL) have been solved, the first by the Grisshammer lab (White et al., 2012). In 
the group of Andreas Plückthun, the structure of NTS bound evolutionary stabilized rat NTR1 
variants have been solved (Egloff et al., 2014). The evolutionary stabilization has been 
described in earlier studies (Sarkar et al., 2008; Schlinkmann et al., 2012). An overview of the 
mutations in the different stabilized variants is shown in Table 1.3. 
Table 1.3. Comparison of the two evolutionary stabilized NTR1 variants TM86V and HTGH4 to wild type NTR1 
Sequential  
numbering 
Ballesteros 
Weinstein 
NTR1 
(rat) 
TM86V HTGH4 
83 1.51 S S G 
86 1.54 A L L 
101 2.38 T T R 
103 2.40 H D D 
105 2.42 H Y Y 
119 2.56 L L F 
121 2.58 M M L 
124 2.61 E E D 
143 3.26 R R K 
150 3.33 D D E 
161 3.44 A V V 
167 3.50 R L L 
213 4.69 R L L 
234 5.35 V L L 
235 5.36 K K R 
240 5.41 V V L 
253 5.54 I A A 
260 5.61 I I A 
262 5.63 N N R 
263 5.64 K K R 
305 6.32 H R R 
332 6.59 C C V 
342 7.26 F F A 
354 7.38 T T S 
358 7.42 F V V 
362 7.46 S A A 
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In a recent study, the structure of NTR1 in complex with Gi1 has been solved via cryo-EM 
(Kato et al., 2019). It was shown that two distinct conformations of activated NTR1 exist when 
bound to the G protein, with a canonical-state promoting the nucleotide exchange and a 
non-canonical state which resembles an intermediate during the activation process. 
1.3. Aim of the Thesis 
The main biological aim of this thesis was to get a better understanding of the GPCR and G 
protein dynamics and their interaction with each other. The structures are already known for 
each of the used proteins, in the case of the NTR1 the first structure is available for nearly a 
decade (White et al., 2012) and even for the thermostabilized variants the crystal structures 
were solved (Egloff et al., 2014). The reason for the choice of NTR1 as a GPCR model for this 
thesis, is its possible production in Escherichia coli (E. coli). Expression in E. coli enables high 
yield and the potential of isotope labeling. Both advantages are needed for the use in nuclear 
magnetic resonance (NMR) spectroscopy. For Gαi,1 the structure was even earlier solved 
(Coleman et al., 1994) due to the fact that it is not a membrane protein. With only crystal 
structures solved, little was known about their dynamics and interaction with each other. To 
this day only one GPCR G protein complex had been solved via x-ray crystallography 
(Rasmussen et al., 2011b), and even the emergence of cryo-EM helps only to solve the complex 
structures, but gives little information about the underlying dynamics of the activation 
process. Therefore, NMR spectroscopy is a powerful tool as shown for other GPCRs (Liu et 
al., 2012). Two main goals should be achieved in this thesis: 
 Obtain deeper knowledge about the structure and dynamics of Gαi,1 in its different 
nucleotide states and the effects on its interaction with an activated GPCR 
 Get a better understanding about the structure and dynamics of the different NTR1 
variants in its different ligand states and how it affects the G protein activation 
The optimization of the size homogeneity and thermal stability of lipid bilayer nanodiscs for 
structural studies was an additional goal of this thesis.  
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2. Methods 
2.1. Expression and purification of recombinant proteins 
2.1.1. Neurotensin Receptor 1 (NTR1) 
The NTR1 constructs used in this thesis are thermostabilized Rattus norvegicus NTR1 variants 
(Egloff et al., 2014). A. Plückthun kindly provided the NTR1 vectors used for this work, as well 
as the vector for the production of an NTR1 specific purification column (Egloff et al., 2015). 
Thereby the NTR1 vectors contain an N-terminal maltose binding protein (MBP) followed by 
a hexa-histidine tag. This is then connected to a human rhinovirus (HRV) 3C protease site 
followed by the truncated (G50-G390, ΔIC3A (V280-I295)) and thermostabilized NTR1 
variants HTGH4 or TM86V. C-terminally of the NTR1, an HRV 3C site is present, followed by 
a penta-asparagine linker, a di-glycine-serine linker and terminally connected to thioredoxin 
A (TrxA), which has a C-terminal deca-histidine tag. 
The NTR1 variants were expressed in NEB Express Iq cells containing the corresponding 
plasmid. After transformation the cells were grown at 37 °C overnight in double yeast 
tryptone (dYT) medium containing 100 µg/mL ampicillin and 2% (w/v) of glucose. The next 
morning the preculture was then used with a 1:40 dilution to inoculate the main culture (dYT 
with 100 µg/mL ampicillin) at 28°C. As soon as the OD600 of the main culture reached a value 
of 0.6-0.8, the expression was induced with 1 mM isopropyl-β-D-Thiogalactopyranoside 
(IPTG) and the culture was incubated overnight. The cells were harvested the next morning 
at 6000 x g for 15 minutes at 4 °C and the bacterial pellets (approximately 3g cells/1L 
expression) were stored an -80 °C until usage. The purification of the NTR1 variants was 
performed as described (Egloff et al., 2014) with some variations. During lysis, liquid stocks 
of DNase I (5µl of 0.1mg/ml stock for 10 ml lysis volume) were used instead of lyophilized 
DNase I powder. 0.6% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS) and 0.12% (w/v) cholesteryl hemisuccinate (CHS) were added as powder to the 
stirring lysis instead as a liquid stock. The buffers for the different purifications steps were 
also different (Table 2.1). 
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Table 2.1. Purification buffers for unlabeled NTR1 variants 
 NT W1 NT W2 SP Bind SP Wash SP Elu SEC 
HEPES pH 8.0 25 mM - - - - 10 mM 
HEPES pH 7.0 - 25 mM 10 mM - 10 mM - 
HEPES pH 7.7 - - - 10 mM - - 
Glycerol 10% (v/v) 10% (v/v) 10% (v/v) 10% (v/v) 10% (v/v) - 
NaCl 600 mM 150 mM - 35 mM 350 mM 150 mM 
DTT - 2 mM 2 mM 2 mM 2 mM 2 mM 
DM 0.5% (w/v) 0.3% (w/v) - - - - 
DDM - - 0.05% (w/v) 0.05% (w/v) 0.05% (w/v) 0.02% (w/v) 
NT1 - - - - 0.5 µM 0.1 µM 
 
If the NTR1 variants were purified in an Antagonist bound state, neurotensin (NT1) was 
omitted from the sulphopropyl (SP) Elution buffer, as well as the size exclusion 
chromatography (SEC) buffer. 
In the case of isotope labeled expressions (see 2.1.4), the purification was identical except for 
the used buffers during the SP chromatography and SEC (Table 2.2) 
Table 2.2. Purification buffers for isotope labeled NTR1 variants 
 NT W1 NT W2 SP Bind SP Wash SP Elu SEC 
HEPES pH 8.0 25 mM - - - - - 
HEPES pH 7.0 - 25 mM 10 mM - 10 mM - 
HEPES pH 7.7 - - - 10 mM - - 
NaPi pH 7.0 - - - - - 20 mM 
Glycerol 10% (v/v) 10% (v/v) 10% (v/v) 10% (v/v) 10% (v/v) - 
NaCl 600 mM 150 mM - 35 mM 350 mM 50 mM 
DTT - 2 mM 2 mM 2 mM 2 mM 2 mM 
EDTA - - - - - 0.5 mM 
DM 0.5% (w/v) 0.3% (w/v) 0.3% (w/v) - - - 
d26-DH7PC - - - 0.5% (w/v) 0.2% (w/v) 0.2% (w/v) 
NT1 - - - - 0.5 µM 0.1 µM 
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2.1.2. Guanine nucleotide-binding protein G(i) subunit alpha 1 (Gαi,1) 
In this work, Guanine nucleotide-binding protein G(i) subunit alpha-1 (Gαi,1) variants from 
Homo sapiens were used. The used vector for all Gαi,1 constructs is a pQE30 vector into which 
the Gαi,1 gene was cloned via polymerase chain reaction (PCR) methods. All variants contain 
an N-terminal hexa-histidine tag, either directly followed by a tobacco etch virus (TEV) 
cleavage site, or immunoglobulin-binding protein G domain B1 (GB1) and then the TEV 
cleavage site. After the TEV cleavage site either the full length protein of Gαi,1 follows, which 
is the case without the GB1 fusion protein, or a truncated Gαi,1 variant missing the first 31 
amino acids (Δ31Gαi,1)  
The protein production is described in detail in the published journals (Goricanec and Hagn, 
2019; Goricanec et al., 2016) and was adapted from an already available protocol (Greentree 
and Linder, 2004). Isotope labeling was done as described in chapter 2.1.4. 
 
2.1.3. Apolipoprotein A-I 
For the use in Nanodisc (ND) production in this work, various membrane scaffold protein 
(MSP) constructs were used. MSP1D1 is a modified protein derived from Apolipoprotein A1. 
The two main constructs were MSP1D1 and the truncated version MSP1D1ΔH5 (Hagn et al., 
2013). Protein expression and purification of MSP1D1 and its variants is explained in detail in 
a recent publication (Hagn et al., 2018; Klopfer and Hagn, 2019). Additionally, a method was 
developed to produce circularized MSP1D1 variants in vivo during expression. The 
corresponding cloning, protein expression, protein purification and Nanodisc assembly is 
described in detail in a recent publication (Miehling et al., 2018). 
 
2.1.4. Isotope labeling Strategies 
In contrast to unlabeled protein expression in E. coli, isotope labeling requires a different 
approach to expression. The transformation of the desired plasmid and the first preculture 
overnight have been done the same way as unlabeled protein expression. As the medium had 
to be changed to D2O from H2O, a careful adaption process had to be done. After the first 
overnight culture has grown densely, it was gently centrifuged (2000 x g for 10 minutes at 
30 °C) so that the bacteria are not put under stress or even damaged. The used medium was 
discarded and, the E. coli were carefully resuspended under sterile conditions with prewarmed 
18 
(37 °C) LB (D2O) or dYT (D2O) containing the corresponding antibiotic and 2% Glucose (w/v) 
both dissolved in D2O. The resuspended culture was then poured into a sterile dry shaking 
flask and again incubated overnight at 37 °C. The next morning the procedure to remove the 
medium was repeated as described previously. The E. coli were now gently resuspended in 
prewarmed (37 °C) “M9 (D2O) general” minimal medium supplemented with the 
corresponding antibiotic and 2% Glucose (w/v) both dissolved in D2O.  
All variants of M9 medium used for different labeling strategies are listed in Table 2.3. The 
liquid stocks were dissolved in D2O and the composition of the used trace elements solution 
is shown in Table 2.4. The solid components as well as the Biotin, Thiamin and antibiotic were 
mixed together in D2O. After complete dissolving of the ingredients, the medium was sterile 
filtered. After sterile filtration the remaining liquid stocks (sterile filtered during preparation) 
were added and the final M9 (D2O) minimal medium properly mixed. If the medium was not 
instantly used, it was sealed with parafilm and stored at 4 °C until usage. 
Table 2.3. Different M9 media used for isotope labeling in E. coli 
 
M9 (D2O) 
general 
M9 (D2O) 
double labeling 
M9 (D2O) 
triple labeling 
Na2HPO4 6 g/L 6 g/L 6 g/L 
KH2PO4 3 g/L 3 g/L 3 g/L 
NaCl 0.5 g/L 0.5 g/L 0.5 g/L 
15NH4Cl 1 g/L 1 g/L 1 g/L 
1H12C Glucose 2 g/L - - 
2H12C Glucose - 2 g/L - 
2H13C Glucose - - 2 g/L 
Biotin (1 mg/ml) 1 mL/L 1 mL/L 1 mL/L 
Thiamin (1 mg/ml) 1 mL/L 1 mL/L 1 mL/L 
Trace elements 
solution (1000x) 
1 mL/L 1 mL/L 1 mL/L 
1 M MgSO4 2 mL/L 2 mL/L 2 mL/L 
0.5 M CaCl2 0.2 mL/L 0.2 mL/L 0.2 mL/L 
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Table 2.4. Trace elements solution 1000x 
 Per 100 mL D2O 
EDTA 5 g 
FeCl3 x 6 H2O 0.83 g 
ZnCl2 84 mg 
CuCl2 x 2 H2O 13 mg 
CoCl2 x 6 H2O 10 mg 
H3BO3 10 mg 
MnCl2 x 6 H2O 1.6 mg 
 
The first M9 preculture was incubated for approximately eight hours at 37 °C and then 
directly added to the prewarmed (37 °C) final preculture, which corresponds to either 
“M9 (D2O) double labeling” or “M9 (D2O) triple labeling” minimal medium, supplemented 
with the needed antibiotic and additional 0.5% of the used glucose type. The final preculture 
is then incubated overnight at 37 °C and the next morning added in a 1:20 ratio to the 
prewarmed (37 °C) corresponding medium. When the OD600 reached a value of 0.6 to 0.7, the 
main cultures were cooled down to the needed expression temperature. In the case of 
13C methyl labeling via specific precursors for isoleucin, leucin, valin and alanin (ILVA 
labeling, see below), the precursors were added at this same time to the culture, as they should 
be added approximately one hour prior to induction. As soon as the OD600 was 0.8 the cells 
were induced with IPTG, the concentration depending on the expressed protein. The induced 
bacteria were grown for 20 h until harvest, which is identical as described for the NTR1 in 
2.1.1. 
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For the 13C methyl labeling of the proteins, specific precursors were used, depending on which 
amino acids should be selectively labeled (see Figure 2.1).  
 
Figure 2.1: Precursors used for the selective isotope labelling of methyl groups and their incorporated position in the protein 
These figures show the precursors used for selective ILVA 13C methyl labelling. The precursors 2-ketobutyric acid-4-13C and 
ethyl 2-hydroxy-2-methyl-13C-3-oxobutanoate for ILV had to be treated with sodium deuteroxide prior to the addition of the 
bacterial culture. This resulted in the precursors 2-ketobutyric acid-4-13, 3-d2 and 3-methyl-13C-2-oxobutanoic acid, 3-d, 4-d3 
which were then used by the E. coli for the incorporation of 13C methyl labeled isoleucine and leucine/valine respectively. 
Alanine was added directly as powder and is not needed to be treated prior to its use 
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Various studies describe the method for selective methyl labelling in detail (Proudfoot et al., 
2019; Tugarinov et al., 2006). In this work, the precursors used for the ILVA labelling scheme 
had to be prepared for their use depending on each precursor. As both the precursor for 
isoleucine (2-ketobutyric acid-4-13C) as well as the precursor for valine/leucine (ethyl 2-hydroxy-
2-methyl-13C-3-oxobutanoate) were obtained in a protonated state at the carbon next to the 13C 
labeled methyl, they had to be treated with NaOD in M9(D2O) to facilitate proton deuterium 
exchange. For this, the precursors which were needed per liter of final medium (see Table 2.5) 
were dissolved in 15 mL/L culture of the medium used. For the isoleucine precursor, the pH 
of the medium was titrated to 10 prior to its addition. After the precursor was added, the 
solution was incubated at 37 °C overnight. The next morning the pH was titrated back with 
DCl to the initial value of the M9 medium and was ready to use. In the case of the 
leucine/valine precursor, the medium was titrated to pH 12 prior to its addition. For this 
precursor, the incubation time at high pH was only 1h at 37 °C. Afterwards the solution was 
titrated back as in the case of the isoleucine precursor. As the alanine precursor was bought 
with complete isotope labeling, it could be directly added without prior treatment. Due to the 
potential for amino acid scrambling of alanine, deuterated succinic acid had to be added to 
the cultures. 2.5 g succinic acid were dissolved in 45 mL of the used medium and the pH had 
to be titrated back to its original value. 
Table 2.5. Amount of deuterated precursors used for ILVA labeling 
 Per 1 L M9 D2O 
2-Ketobutyric acid-4-13C 80 mg 
Ethyl 2-hydroxy-2-methyl-13C-3-oxobutanoate 300 mg 
L-Alanine-3-13C, 2-d 800 mg 
Succinic acid-2,2,3,3-d4 2.5 g 
 
In order to obtain 13C methyl labelled samples, a second method was also used. Unlabeled 
proteins can be tagged with S-Methyl-13C methanethiosulfonate (13C MMTS). Thereby all 
accessible cysteines are tagged with a 13C methyl group (see Figure 2.2). 
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Figure 2.2: Tagging of accessible cysteines with MMTS  
Here, the chemical basis of MTS tagging of cysteines with MMTS is shown. This reaction is also reversible to a certain degree, 
but the methanesulfonyl hydride is not stable in H2O and reacts to methanesulfonate (not shown in this figure). 
 
In a first step, the protein to be tagged (in this work the NTR1 variants in n-Dodecyl β-D-
maltoside (DDM)) needs to be buffer exchanged to no dithiothreitol (DTT). This is 
accomplished by centricon buffer exchange. The relevant fractions of the NTR1 variant are 
pooled (3 mL total volume for 6 S200a fractions) and then filled to 15 ml with MMTS tagging 
buffer (50 mM NaPi pH 7.5, 1 mM EDTA, 0.02 % (w/v) DDM) and concentrated to 1 mL at 
3400 x g and 4 °C. The concentrated sample is again filled up to 15 mL with MMTS tagging 
buffer and again concentrated to 1 mL at 3400 x g and 4 °C. This step is repeated 2 more times. 
Then the concentration of the NTR1 variant is determined and a 10-fold molar excess (relative 
to the cysteines) of MMTS (100 mM stock in dimethyl sulfoxide (DMSO)) is added. This 
reaction mixture is then incubated at 4 °C overnight on a shaking plate. The next morning the 
reaction is stopped by buffer exchange via centricon concentration. The 1 mL reaction 
mixture is filled to 15 mL with NMR buffer (20 mM NaPi pH 7.0, 50 mM NaCl, 1 mM EDTA, 
0.02 % (w/v) DDM). These 15 mL are then concentrated to 1 mL at 3400 x g and 4 °C. This is 
repeated 3 more times and during the last centrifugation step, the sample is concentrated to 
the lowest possible volume in the centricon (250 µL). After this final step, the samples are 
ready for NMR measurement. This protocol was adapted from a previous published work in 
the group of Prof. Lewis Kay (Religa et al., 2011). 
 
2.2. Nanodisc assembly 
Membrane proteins outside of lipid bilayers tend to denature or show a not physiological 
behavior. Before the emergence of nanodiscs only lipid vesicles could be used as a native-like 
membrane mimetic. Their disadvantages in the use of structural biology are the big size, the 
lack of size homogeneity, solubility and stability. Therefor nanodiscs present an effective way 
for structure determination of membrane proteins in a lipid environment (Bayburt and Sligar, 
2010; Denisov and Sligar, 2016, 2017). 
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Nanodiscs consist of a phospholipid bilayer wrapped by two amphipathic helical belt proteins 
called membrane scaffold proteins (MSPs), schematically shown in Figure 2.3. The structure 
of nanodiscs was confirmed via NMR spectroscopy (Bibow et al., 2017). MSP is derived from 
human Apolipoprotein A1 (ApoA1) which is part of high density lipoprotein (HDL) particles 
(Brouillette et al., 2001). 
 
Figure 2.3: Structural model of a nanodisc  
In this figure an empty nanodisc is shown schematically. Two alphahelical proteins (orange/grey) form a belt around the lipid 
bilayer. These proteins are derived from Apolipoprotein A1 (ApoA1) and are called membrane scaffold proteins (MSPs). The 
length of the MSPs determines the diameter of the nanodiscs. The lipids used for nanodiscs can be varied in their fatty acid 
chain length as well as in their head groups (red). Also, mixtures of lipids or even extracts from biological material can be used 
as source for the lipids. 
 
Nanodiscs are mainly used for 2 different applications in biochemistry. They are suitable for 
the reconstitution of membrane proteins in a lipid bilayer. Additionally, nanodiscs can be used 
as a model membrane surface of defined lipid composition. 
Empty nanodiscs as well as membrane protein containing nanodiscs can be assembled via 
gradual detergent removal of detergent solubilized assembly mixtures consisting of lipids, 
MSP and optionally membrane proteins. The detergent removal is accomplished via 
hydrophobic adsorption (bio beads) or dialysis (Bayburt et al., 2002; Bayburt and Sligar, 2010). 
The protocol for the assembly of nanodiscs is flexible and therefor it can be optimized for 
each membrane protein. Parameters which can be optimized are the temperature, time, 
amount of adsorbent or choice of detergent to name only some. An important factor in 
nanodisc assemblies is the determination of the correct stoichiometric ratio of MSP, lipid and 
the membrane protein, especially if a desired monomeric or oligomeric state of the membrane 
protein is desired. 
The basic MSP variant MSP1D1 has been optimized for NMR by the creation of truncated 
variants resulting in nanodiscs of smaller diameter (Hagn et al., 2013; Hagn et al., 2018; 
Klopfer and Hagn, 2019). 
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2.2.1. Assembly of empty Nanodiscs 
In order to assemble empty nanodiscs, MSP and lipids are mixed in MSP buffer (20 mM Tris 
pH7.5, 100 mM NaCl, 0.5 mM EDTA). Depending on the MSP variant and which lipids were 
used, the assembly ratios had to be adapted. The final concentration of cholate during 
assembly was always 20 mM. For empty MSP1D1 nanodiscs with 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) as lipid, the ratio between MSP and lipid was 1:35. In the 
case of MSP1D1dH5 and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or 1,2-
dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG), the ratio between MSP and lipid was 
1:50. Upon pipetting the nanodisc assembly mixture, the reactions were left to incubate for 
1 h. POPC containing nanodisc assembly mixtures needed to be incubated on ice due to the 
phase transition point of POPC. In the case of DMPC, the assemblies could be performed at 
room temperature. Afterwards polystyrene bio beads were added to the reaction mixtures 
(0.7 g bio beads/1 mL reaction mixture) and incubated for 3 h on a shaking plate. Then the bio 
beads were removed from the reaction mixture and latter was applied to a S200 size exclusion 
chromatography column. The fractions containing the empty nanodiscs were pooled and 
ready for further work. The procedure is described in more detail a recently published work 
(Hagn et al., 2018). 
2.2.2. Reconstitution of NTR1 into Nanodiscs 
To obtain nanodiscs containing NTR1 variants, the above-mentioned protocol had to be 
modified. Additional to MSP1D1 and the lipids (POPC in the case of NTR1), the GPCR had to 
be added to the reaction mixture. In order to obtain nanodiscs with monomeric NTR1, an 
excess of MSP1D1 had to be used. The molar ratio between MSP and the GPCR was 1:20, so 
only 1 nanodisc contains the NTR1 per 9 empty discs. As the nanodiscs are not completely 
empty, a different lipid to MSP ratio was used. Only 25 POPC per 1 MSP was added to the 
reaction mixture. Also, the MSP buffer was modified by an addition of 10 mM 
β-mercaptoethanol (β-ME) as the GPCR contains cysteines. The assembly was incubated on 
ice for 2 h. Afterwards 0.5 g Biobeads/1 mL assembly were added and incubated at 4 °C on a 
shaking plate for 2 h. Then 0.3 g bio beads/1 mL assembly were added additional to the 
mixture with another 2 h incubation time at 4 °C. Afterwards, the bio beads were separated 
via an empty gravity flow column and washed with 5-fold excess (relative to the assembly 
volume) of MSP buffer with β-ME. The assembly mixture with the wash fraction were pooled 
and dialyzed against SP binding buffer (10 mM HEPES pH 7, 10 mM β-mercaptoethanol 
(β-ME)) overnight at 4 °C. The dialyzed nanodisc pool was then applied onto a SP FF hiTrap 
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column and washed and eluted with a NaCl gradient from 10 mM to 1 M. At around 300 mM 
the NTR1 containing nanodisc eluted, whereas the empty nanodiscs could be found in the 
flow through. The final purification step was a size exclusion chromatography (S200a) of the 
concentrated pool of NTR1 nanodiscs. 
2.3. Biophysical methods 
2.3.1. Circular dichroism spectroscopy 
Circular dichroism (CD) spectroscopy reveals information about the secondary structure of 
proteins (Greenfield, 2006b). If circularly polarized light interacts with asymmetric molecules, 
the left-handed circularly polarized light is absorbed differently than the right-handed 
circularly polarized light (Beychok, 1966). The angle of the rotated plane of light is defined as 
degree ellipticity θ. The molar ellipticity [θ] is defined as  
[𝜃] =
𝑑𝑒𝑔 ∙ 𝑐𝑚2
𝑑𝑚𝑜𝑙
 
Different structural elements show different CD spectra (see Figure 2.4). 
 
Figure 2.4: Exemplary CD spectra for different secondary structure elements 
These CD spectra are examples, depending on the predominant secondary structure which is mainly present in the investigated 
proteins. As GPCRs are nearly pure alpha helical proteins, they show a classic alpha helical CD spectrum. Therefor they always 
showed two distinct minima around 222 nm and 209 nm. The former was used as a reference wave length for thermal 
denaturation experiments in CD spectroscopy. 
 
α-helical proteins show minima at 208 nm and 222 nm and a maximum at 193 nm (Holzwarth 
and Doty, 1965). Proteins with β-sheet secondary structures show a minimum at 218 nm and 
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a maximum at 195 nm (Greenfield and Fasman, 1969). Disordered proteins show a minimum 
at 195 nm and a weak maximum at 210 nm (Venyaminov et al., 1993). 
As the proteins have different sizes, their molar ellipticity needs to be normalized in order to 
compare different proteins via CD spectroscopy. This is done with the mean residue molar 
ellipticity: 
𝜃𝑀𝑅𝐸 =
𝜃(𝑚𝑑𝑒𝑔) ∙ 106
𝑑(𝑚𝑚) ∙ 𝑐(𝜇𝑀) ∙ 𝑛
 
In this formula d is the pathlength in mm, c is the protein concentration in µM and n is the 
number of peptide bonds in the protein. 
CD spectroscopy can also be used to determine the thermal stability of proteins (Greenfield, 
2006a). 
The CD spectra were recorded on a Jasco J-715 spectropolarimeter. The concentration of the 
samples recorded was 5 µM, dissolved in CD buffer (10 mM NaPi pH 7.0, 10 mM β-ME; for 
NTR1 samples in detergent micelles additional 0.02 % (w/v) DDM or 0.2 % (w/v) DH7PC was 
added). 
The wavelength spectra were recorded from 260 nm to 190 nm in 0.5 nm intervals at 20 °C. 5 
measurements were accumulated. Points recorded with a voltage of higher than 800 were 
excluded from analysis. 
Thermal denaturation spectra were recorded at a wavelength corresponding to the global 
minimum of the protein, in the case of α-helical proteins at 220-222 nm. The temperature was 
ramped at a rate of 1 °C/min from 20 °C to 100 °C. 
2.3.2. Fluorescence spectroscopy 
The Förster resonance energy transfer (FRET) is a mechanism of radiationless energy transfer 
from a fluorescence donor to a fluorescence acceptor (Lakowicz, 2013). Thereby the 
fluorescence donor is excited by a specific wavelength and transfers its energy to the 
fluorescence acceptor reach the ground state. The fluorescence acceptor emits the energy 
through a distinct wavelength in order to get also back to its ground state. This emission is 
then detected. The phenomenon was first described by Theodor Förster more than 70 years 
ago (Förster, 1948). The efficiency of the FRET depends correlates to the distance between the 
donor fluorophore and acceptor fluorophore. This enables to map the distance between both 
or to check binding kinetics. In this study, the binding kinetics of fluorescence labeled 
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nucleotides to Gαi,1 were investigated. The fluorescence label used was N-Methylanthraniloyl 
(MANT) bound to the 3’-OH of the ribose from the nucleotide. In order to obtain the KD values 
for the binding affinity of the nucleotides, Gαi,1 was titrated in increasing concentrations to a 
buffer containing the MANT labeled nucleotide. Another experiment performed was the 
determination of the binding and dissociation kinetics of GDP or GTP to GNAI. Therefor 
presatured Gαi,1 with MANT-GDP or MANT-GTP was incubated with an excess of unlabeled 
GDP or GTP and the decay of the Fluorescence signal was measured. The exact method was 
described in a recent work (Goricanec et al., 2016). 
2.4. NMR Spectroscopy 
NMR is a powerful tool to investigate the structure and dynamics of biomolecules. The 
physical basis of NMR is the magnetic dipolar momentum (µ). µ consists of the gyromagnetic 
ratio (γ) and the spin quantum number (I) and in this formula only the z-component is shown: 
𝜇𝑧 = 𝛾 ∙ 𝐼𝑧 
The gyromagnetic ratio is a nucleus specific factor, whereas the spin quantum number 
depends on the number of unpaired protons (p) and neutrons (n) in the nucleus. If p = n then 
I is zero and therefore not detectable via NMR. In biomolecular NMR, only nuclei with I=1/2 
are used (i.e. 1H, 13C, 15N). 
If an external magnetic field (B) acts on the magnetic dipolar momentum (µ), the resulting 
magnetic moment (M = E) can be described as: 
𝐸 = 𝜇 ∙ 𝐵 
Putting both equations together and defining 𝐼𝑧 = ℏ ∙ 𝑚𝑧 leads to the following 
equation: 
𝐸 = 𝛾 ∙ 𝐵 ∙ ℏ ∙ 𝑚𝑧 
For spin ½ nuclei, two energy states can be defined: 
𝐸𝛼 =
1
2
∙ 𝛾 ∙ 𝐵 ∙ ℏ and  𝐸𝛽 = −
1
2
∙ 𝛾 ∙ 𝐵 ∙ ℏ 
The spins with these energy levels precise along the magnetic field B in the Larmor frequency: 
𝜔𝐿𝑎𝑟𝑚𝑜𝑟 = 𝛾 ∙ 𝐵 
If the low spin state is excited with a radio frequency pulse according to the Larmor frequency, 
it is flipped to the high spin state. This difference in energy between the 2 states can be 
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detected via the fast induction decay (fid) when the high spin state flips back to the low spin 
state: 
∆𝐸 = 𝛾 ∙ 𝐵 ∙ ℏ  or ∆𝐸 = 𝜔𝐿𝑎𝑟𝑚𝑜𝑟 ∙ ℏ 
In order to maximize the energy difference, the magnetic field strength can be increased as 
well as using nuclei with a high gyromagnetic ratio (especially 1H) for excitation and 
detection.  
The population of the spin states is distributed according to the Boltzmann distribution: 
𝑁𝛽
𝑁𝛼
= 𝑒
−∙𝛾∙𝐵∙ℏ
𝑘𝐵∙𝑇  
As each nucleus has a small difference in its frequency depending on the electron distribution 
in his surrounding, with the effect being called chemical shift. 
This chemical shift difference is normalized relative to sodium trimethylsilylpropane-
sulfonate (DSS) in the case of 1H and 13C. As the frequency differences are small, they are 
multiplied by 106 for an easier handling and therefor called ppm. 
𝛿 =
𝜈 − 𝜈𝐷𝑆𝑆
𝜈𝐷𝑆𝑆
 [𝑝𝑝𝑚] 
All performed NMR experiments were acquired on the following instruments: Bruker 
AvanceIII spectrometers operating at 950, 900, 800 and 600 MHz proton frequency, each 
equipped with a cryo TCI triple resonance (1H, 13C, 15N) z gradient probe.  
The general NMR buffer contained 20 mM sodium phosphate with a pH of 7.0 and 50 mM 
sodium chloride. If the sample contained cysteines and should be in a reduced state, 2 mM 
DTT was added. In the presence of Gαi,1 no EDTA could be added as MgCl2 (concentration 
twice the nucleotide concentration in the sample) was needed as cofactor. Nucleotides for 
Gαi,1 were added in a twofold molar excess relative to the protein. The concentration of EDTA 
was 0.5 mM if no Gαi,1 was present in order to improve long term stability (inhibition of 
metalloproteases). 7-10% D2O were added to gain a lock for the sample. 
The spectra were recorded and processed with Bruker TopSpin 3.5 pl7. NMRFAM-SPARKY 
was used to analyze and display the NMR spectra (Lee et al., 2015). 
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2.4.1. NMR resonance assignment 
NMR does not only provide information via the chemical shift but also due to magnetic 
coupling. Magnetic coupling can happen through covalent bonds or through space. This 
information can then be used to determine the structure on an atomic level.  
Couplings through electrons of covalent bonds are called J-couplings or scalar couplings. J-
couplings lead to multiplet splitting of the corresponding peaks, dependent on the chemical 
environment. The distance in the splitting is corresponding to the coupling constant J of the 
observed coupling and the size depends on the strength of the coupling. Typically, J-couplings 
are observed between 1 and 3 covalent bonds. Typically, the first recorded NMR experiment 
is a 1H 1D. This gives a first overview about the sample quality and can be used to determine 
the presence of small molecules in the sample like detergents or nucleotides. 
The next step is to record a 2D NMR of the labeled sample. Thereby the magnetization is 
transferred from the proton to the heteronucleus via an insensitive nuclei enhanced by 
polarization transfer (INEPT) pulse sequence (Morris and Freeman, 1979). For backbone 
assignment experiments, this is usually a 1H15N heteronuclear single quantum coherence 
(HSQC) spectrum. For each proton bound to a nitrogen, one specific peak arises. This is true 
for all backbone amides (except for prolines which are imides and therefore not detectable) 
which also explains why this spectrum is called the fingerprint spectrum of proteins. 
Additionally, sidechain amides are visible, but due to their distinct chemical shifts they appear 
in different regions of the spectrum.  
For big proteins, signal overlap can be a problem. This is circumvented mainly by two 
methods. The signal overlap caused by line broadening originates from increased relaxation 
rates due to the 13C-1H dipolar interactions. By deuterating the carbon at not exchangeable 
positions, this effect can be decreased by approximately factor 15, resulting in narrower peaks 
and therefor better resolution (Gardner and Kay, 1998). Also, the pulse sequence can be 
optimized in order to minimize the transverse relaxation of 1H, 13C and 15N. The pulse 
sequence used to accomplish this goal is the transverse relaxation-optimized spectroscopy 
(TROSY) which minimizes the dipole-dipole coupling and chemical shift anisotropy causing 
the transverse relaxation in a 1H 15N 2D NMR spectrum (Pervushin et al., 1997). It could also 
be shown that this TROSY effect can also be observed in 1H 13C heteronuclear multi quantum 
coherence HMQC spectra compared to 1H 13C HSQC spectra, therefor the HMQC with 
improved sensitivity for high molecular weight (MW) proteins is called “methyl TROSY” 
(Tugarinov et al., 2003). 
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The next step in the assignment of proteins is accomplished by using 3D NMR experiments. 
Thereby the magnetization is additionally transferred a second time, from the first 
heteronucleus (15N) to the second heteronucleus (13C). A big set of heteronuclear 
multidimensional NMR experiments can then be used to assign the resonances for the 
protons, amide nitrogen and alpha and beta carbon for each amino acid in the protein (Sattler 
et al., 1999). The 3D experiments can also be combined with the TROSY pulse sequence for 
further improvement of sensitivity. This was shown for the [15N,1H]-TROSY-HN(CO)CA, 
[15N,1H]-TROSY-HN(CA)CO, [15N,1H]-TROSY-HNCACB, [15N,1H]-TROSY-HN(CO)CACB 
(Salzmann et al., 1999), [15N,1H]-TROSY-HNCA and [15N,1H]-TROSY-HNCO (Salzmann et al., 
1998). In this work, the TROSY type 3D NMR experiments were used for the assignment of 
Gαi,1. With the residue specific Cα and Cβ chemical shifts, a secondary structure prediction 
can be done (Spera and Bax, 1991). 
 
Figure 2.5: Assignment strategy 
This is an overview of the NMR assignment experiments which were performed for the proteins in this work. The starting point 
is always a 2D 1H-15N fingerprint spectrum. There is also always a pair of two experiments for each carbon to be assigned. The 
HNCA experiment correlates Cα and Cα-1 chemical shifts with the corresponding 1H and 15N chemical shift. In the case of the 
HN(CO)CA only the Cα-1 chemical shift is correlated with the corresponding 1H and 15N chemical shift. The HNCO experiment 
correlates Ccarbonyl and Ccarbonyl-1-1 chemical shifts with the corresponding 1H and 15N chemical shift. In the case of the 
HN(CA)CO only the Ccarbonyl-1 chemical shift is correlated with the corresponding 1H and 15N chemical shift. The HNCACB 
experiment correlates Cα and Cα-1 as well as Cβ and Cβ-1 chemical shifts with the corresponding 1H and 15N chemical shift. In 
the case of the HN(CO)CACB only the Cα-1 as well as Cβ-1 chemical shift is correlated with the corresponding 1H and 15N 
chemical shift. 
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2.4.2. NMR relaxation experiments 
Relaxation in NMR is the phenomenon of the excited spins returning to their Boltzmann 
equilibrium magnetization. In an external magnetic field B (along z-axis), the spins align along 
to this field. This results in a net magnetization M0. This bulk magnetization along z is 
unaligned in x and y direction, so no transverse magnetization is present. If a 90° radio 
frequency pulse is applied to M0, the magnetization flips into the xy-plane and precesses 
around the z-axis in the Larmor frequency causing transverse magnetization. Due to 
relaxation mechanisms like dipolar spin-spin interactions or chemical shift anisotropy, this 
transverse magnetization decays over time and finally coherence is lost. The time for this loss 
of coherence in the xy plane is called the T2 relaxation time, or spin-spin relaxation time. 
Parallel to the T2 relaxation, the magnetization is also going back to its equilibrium along the 
z-axis. The time needed to reach the net magnetization M0 is called the T1 relaxation time, or 
spin-lattice relaxation time see Figure 2.6.  
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Figure 2.6: T1 and T2 relaxation 
These are the physical basis of the NMR experiments. (A) Without an external magnetic field, the spins are randomly oriented 
in a random phase and therefor no net magnetization is detected. As soon as an external magnetic field B0 is applied, the spins 
align to the magnetic field and magnetization can be observed. Thereby the spins precess around the z axis. (B) If a radio 
frequency (rf) pulse is applied, the spins flip into the xy plane. As the spins are precessing, the coherence is lost and the spins are 
randomly distributed over time in the xy plane. The time to reach this equilibrium is the T2 relaxation time. (C) This graph 
shows exemplary the T2 relaxation over time. (D) The spins which have no magnetization in z direction reach again the starting 
net magnetization in an external magnetic field. The time to reach this equilibrium is the T1 relaxation time. (E) This graph 
shows exemplary the T1 relaxation over time. 
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Figure 2.7: Correlation of T1 and T2 with varying τc 
Here is a representation on how the relaxation rates T1 and T2 correlate with different correlation times τc. T1 represents the 
time needed to reach the net magnetization in z, therefor it is dependent on the magnetic field B. T2 in contrast is only 
dependent on the molecular size and viscosity of the sample 
 
The correlation time (τc) defines the time needed for a molecule to rotate on average 1 rad. 
The bigger the molecule, the bigger is the correlation time. Figure 2.7 shows the correlation 
between correlation time (and therefore molecular size) and relaxation times T1 and T2. As T1 
is the time needed to reach the net magnetization in z direction it is dependent on the 
magnetic field B. 
In order to get a better understanding of protein dynamics in the µs to ms range, Carr-Purcell-
Meiboom-Gill (CPMG) relaxation dispersion (RD) NMR experiments can be done (Neudecker 
et al., 2009). A protein existing in two discrete conformations (A and B), means that certain 
nuclei will have different chemical shifts, correlating to different rotation frequencies ωA and 
ωB (see Figure 2.8 A). If after an evolution time of T/2 a 180° pulse is applied to this sample, 
the phase is inverted and after another T/2 evolution time and the phases are refocused (see 
Figure 2.8 B). This pulse sequence is also known as CPMG pulse sequence. In the case where 
exchange is occurring between state A and state B, the precession frequency will fluctuate 
between ωA and ωB. This leads to an incomplete refocusing of the magnetization with the 180° 
pulse (see Figure 2.8 C). The more refocusing pulses are applied during the delay T, the better 
the refocusing works and therefore the effects of chemical exchange are decreased (see Figure 
2.8 D). 
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Figure 2.8: Theoretical background to relaxation dispersion NMR spectroscopy. 
(A) Certain nuclei will have two different chemical shifts, correlating to two different rotation frequencies ωA and ωB, in a 
protein having two discrete conformations (here named A and B). (B) This means that, if after an evolution time of T/2 a 180° 
pulse is applied to this sample, the phase is inverted and after another T/2 evolution time and the phases are refocused (CPMG 
pulse sequence). (C) When exchange occurs between state A and state B, the precession frequency will fluctuate between ωA and 
ωB resulting in an incomplete refocusing of the magnetization with the 180° pulse. (D) With more refocusing pulses during the 
delay T, the refocusing is improved and therefor the effects of chemical exchange are decreased. 
 
In CPMG relaxation dispersion NMR experiments the signal intensity I of the ground state A 
for a certain spin probe is observed with varying repetition rates of the refocusing pulses. 
This function is I(νCPMG) with νCPMG = 1/(2τ) and τ being the time between the 180° pulses. 
I(νCPMG) can then be converted to a site specific effective transverse relaxation rate Reff(νCPMG) 
= -ln(I(νCPMG)/I0)/T with I0 being a reference signal intensity. With Reff(νCPMG) the exchange 
rates kAB and kBA can be calculated via the Bloch-McConnell equations (McConnell, 1958). 
The probes used for CPMG RD NMR experiments can be backbone HN groups or methyls, 
where preferably protonated and 13C-labeled methyls in a highly deuterated background are 
being used for large (membrane-)protein systems. 
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2.4.3. NMR RDC experiments 
The magnetic field of a nucleus depends due to dipole-dipole interactions on the magnetic 
field of its neighboring nuclei. This interaction is the dipolar interaction. The strength of the 
dipolar interaction depends on the distance (r), the relative orientation (θ) of the nuclei to the 
external magnetic field and their gyromagnetic ratios (γ): 
𝐷𝐼𝑆(𝜃) =
ℏ ∙ 𝛾𝐼 ∙ 𝛾𝑆
4 ∙ 𝜋2 ∙ 𝑟𝐼𝑆
3 ∙ (1 − 3 ∙ cos
2 𝜃) 
In solution state NMR, the dipolar interaction is on average zero due to the molecular motion. 
If alignment media are used, the molecular motion can be slowed down and partial alignment 
can be achieved (Tjandra and Bax, 1997). In this study liquid crystalline medium was used to 
achieve partial alignment but also other alignment media like the filamentous bacteriophage 1 
(Pf1) have been used for alignment (Zweckstetter and Bax, 2001). As not only the distance can 
be calculated by residual dipolar couplings (RDCs) but also the relative orientation, a precise 
determination of relative domain orientation is possible. In order to determine the RDCs, two 
NMR measurements (TROSY and semi-TROSY) need to be done with alignment medium 
(showing J coupling and dipolar coupling) and without alignment medium (showing only J 
coupling). With the TROSY and semi-TROSY the J coupling can be determined whereas the 
comparison of the isotropic and anisotropic state leads to the dipolar coupling. To perform 
the structure calculation XPlor-NIH was used (Schwieters et al., 2003), the back calculation of 
RDCs was accomplished via PALES (Zweckstetter, 2008). The resulting R factor, representing 
the correlation between the experimental and back-calculated RDCs, allows an estimation of 
the agreement of the couplings with a specific 3D structure.  
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3. Publications 
As my doctoral work will be written as a publication-based dissertation, I will summarize all 
published articles I was part of. Special focus will be put on the articles where I am the first 
author. All relevant data, which have not been published so far, will be presented in detail in 
the appendix. 
3.1. Conformational dynamics of a G-protein α subunit is 
tightly regulated by nucleotide binding 
This article (Goricanec et al., 2016) has been published on the 13th of June 2016 in the journal 
PNAS. “Conformational dynamics of a G-protein α subunit is tightly regulated by nucleotide 
binding” can be accessed online via http://doi.org/10.1073/pnas.1604125113. David Goricanec 
contributed as the 1st author to this publication. Due to summarizing the article in the following, 
I will not mention the citations of the original article (Goricanec et al., 2016). 
Heterotrimeric G-proteins are important transducers of GPCR signaling. To get a better 
understanding of this signaling pathway, the structure and dynamics of the involved proteins 
have to be better understood. A key role in this signaling process is the interaction between 
the heterotrimeric G-protein and the corresponding GPCR. This work mainly focused on the 
G-protein side, to be more precise on the inhibiting G-protein α subunit 1 (Gαi,1) and its 
structure and dynamics, depending on its ligand state and if there is an activated GPCR 
present.  
In this work I produced the 2H 13C 15N labeled Δ31Gαi,1 for the planned NMR studies. Via 
FRET measurements it was by previous work shown that Δ31Gαi,1 has a very similar 
nucleotide binding behavior compared to the full length Gαi,1, but with preferable spectral 
quality in NMR measurements. The labeled Δ31Gαi,1 was purified by myself in three different 
ligand states: apo, GDP-bound and GMPPNP-bound (GMPPNP was used as a more hydrolysis 
stable GTP analogue). Additionally, I produced unlabeled agonist bound HTGH4-L167R as 
active NTR1 for the studies. With this GPCR I made nanodiscs as well as empty nanodiscs as 
an empty membrane reference. With all the material I produced, nine different NMR samples 
were made, each containing either apo, GDP-bound or GMPPNP-bound Δ31Gαi,1 combined 
with either only NMR buffer, empty MSP1D1 POPC nanodiscs or MSP1D1 POPC nanodiscs 
containing NT1-bound HTGH4-L167R. Those samples were used for the backbone 
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assignment of Δ31Gαi,1 as well as for the mapping of chemical shift perturbations and peak 
intensities for the different ligand states and for the presence or absence of an activated GPCR. 
These results, as well as the results of the other experiments, lead to the conclusion that 
GTP-bound Δ31Gαi,1 (or bound to GTP analogues) shows little dynamics due to tight binding 
of the nucleotide. It was also shown that it has little to no affinity to the activated GPCR, as 
one would suspect due to signaling physiology. In line with this result, apo and GDP-bound 
Δ31Gαi,1 showed a higher degree of flexibility and a more open conformation. This led to the 
finding of two distinct conformational states of Δ31Gαi,1, to be more precise of its Ras domain. 
The population levels are defined by the ligand state and the presence of a GPCR. The open 
state has a high affinity to an activated GPCR and is even more stabilized by the binding to 
the GPCR. In contrast to this, the closed state does not interact with the GPCR. 
 
3.2. NMR backbone and methyl resonance assignments of an 
inhibitory G-alpha subunit in complex with GDP 
This article (Goricanec and Hagn, 2019) has been published on the 11th of December 2018 in the 
journal Biomolecular NMR Assignments. “NMR backbone and methyl resonance assignments of 
an inhibitory G-alpha subunit in complex with GDP” can be accessed online via 
https://doi.org/10.1007/s12104-018-9865-9. David Goricanec contributed as the 1st author to this 
publication. Due to summarizing the article in the following, I will not mention the citations of 
the original article (Goricanec and Hagn, 2019). 
As shown in 3.1, NMR analysis of proteins is necessary to obtain high quality data on the 
dynamics and conformational states of proteins, in this case of Δ31Gαi,1. But to be able to 
perform these experiments, a detailed assignment of the relevant protein is needed. In the 
first study (Goricanec et al., 2016), only the GMPPNP bound Δ31Gαi,1 was assigned in detail. 
For the GDP-bound Δ31Gαi,1, some assignments were missing, due to severe resonance 
broadening of this dynamic ligand state.  
In this study, I published the backbone and methyl group resonance assignments for the 
GDP-bound form using an ILVA-labeled protein sample. The main focus of this work, was to 
report a detailed assignment of Δ31Gαi,1 in the GDP-bound form, to complement the already 
published detailed assignment of the GMPPNP-bound form of Δ31Gαi,1 from the previous 
study (Goricanec et al., 2016). 
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With those two assignments, future research in the GPCR G-protein interaction as well as the 
dynamic processes is enabled. For the necessary NMR studies in this context, the resonance 
assignments are of elementary need. 
 
3.3. A Split-Intein-Based Method for the Efficient Production 
of Circularized Nanodiscs for Structural Studies of 
Membrane Proteins 
This article (Miehling et al., 2018) has been published on the 27th of June 2018 in the journal 
CHEMBIOCHEM. “A Split-Intein-Based Method for the Efficient Production of Circularized 
Nanodiscs for Structural Studies of Membrane Proteins” can be accessed online via 
https://doi.org/10.1002/cbic.201800345. David Goricanec contributed as the 2nd author to this 
publication. Due to summarizing the article in the following, I will not mention the citations of 
the original article (Miehling et al., 2018). 
To study the structural biology of membrane proteins, phospholipid nanodiscs have recently 
gained in popularity. In contrast to detergent micelles, nanodiscs resemble a native-like 
environment. Although they exist for nearly two decades, only recently their use in structural 
biology increased. One of the reasons was their optimization for structural biology via 
different sizes. Still their thermal stability as well as their size homogeneity varied from MSP 
to MSP variant. An approach to overcome this problem are covalently circularized nanodiscs. 
There were already methods available to produce covalently circularized nanodiscs, but they 
were difficult to produce and it was a time-consuming process. The aim of this project was 
an easy and fast method, preferably in vivo, to produce circularized membrane scaffold protein 
(cMSP) of different sizes for a covalently circularized nanodisc preparation. 
I was involved in the design of the cMSP constructs in the beginning and for the establishment 
of the first protein production and purification steps. The initial step, was to design the PCR 
to clone the Nostoc punctiforme DnaE split-inteins before and after the MSP sequence. To 
stablish this method, MSPΔH5 was used as a scaffold. After successful cloning, I optimized 
the expression of cMSP in E. coli, especially under the goal to maximize monomeric cMSP 
expression. As a last step, the first steps of the purification have been established. Following 
this ground laying work, Jonas Miehling continued and finished the project completely by 
himself. 
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In this work it could be seen via electron microscopy, that the circularized nanodiscs showed 
better size homogeneity. Additionally, they had a higher thermal stability as CD data proofed. 
Both effects were leading to better spectra in NMR. The membrane proteins used in the 
circular nanodiscs to confirm this phenomenon were bacterial outer membrane protein X 
(OmpX) and human voltage-dependent anion channel subtype 1 (VDAC1). Both showed 
better spectra in circularized than linear MSP derived nanodiscs. With VDAC1 containing 
nanodiscs it could also be seen that higher measurement temperatures for NMR are possible, 
what also enabled better spectral quality. 
 
3.4. Stabilization and structural analysis of a membrane-
associated hIAPP aggregation intermediate 
This article (Rodriguez Camargo et al., 2017) has been published on the 17th of November 2017 in 
the journal eLIFE. “Stabilization and structural analysis of a membrane-associated hIAPP 
aggregation intermediate” can be accessed online via https://doi.org/10.7554/eLife.31226.001. 
David Goricanec contributed as the 5th author to this publication. Due to summarizing the article 
in the following, I will not mention the citations of the original article (Rodriguez Camargo et al., 
2017). 
Many diseases are caused by protein aggregation and amyloid formation, i.e. human islet 
amyloid polypeptide (hIAPP) in the case of type II diabetes. It is also known that many of 
those proteins interact with cell membranes causing unique protein folding patterns or even 
promote amyloid formation. In this work it has been shown that nanodiscs can be used to 
mimic membrane-associated protein aggregation. The used amyloigenic polypeptide in this 
study was hIAPP and the structural analysis has been done mostly via solid state NMR 
spectroscopy.  
My part of this work was to produce different types of nanodiscs, varying in size but especially 
in lipid composition. First it was checked which size of nanodiscs is needed, what could be 
concluded to be MSP1D1ΔH5, as MSP1D1 would have been unnecessarily too big. The next 
step was the screening of different lipid ratios, to influence the charge of the membrane 
surface. Whereas DMPC has a net charge of zero, DMPG has a negative net charge. Therefor 
I produced the nanodiscs with the following three ratios (90% DMPC/10% DMPG, 
75% DMPC/25% DMPG, 50% DMPC/50% DMPG). From those nanodiscs, the one with the ratio 
90% DMPC/10% DMPG caused the most stable nanodisc hIAPP intermediate.  
41 
It was shown that nanodiscs are suitable to study amyloid membrane interactions in a native 
like environment and this could also be used for the investigation of other amyloigenic 
polypeptides.  
 
  
42 
 
  
43 
4. Discussion 
The main goal of this thesis was to get a better understand in the GPCR G protein signaling 
process (see Figure 4.1).  
The first part of the work mainly focused on the G-protein side, to be more precise on the 
inhibiting G-protein α subunit 1 (Gαi,1) and its structure and dynamics, depending on its 
ligand state and if there is an activated GPCR present. Thereby I first labeled Δ31Gαi,1 (2H 13C 
15N) for the planned NMR studies. FRET measurements done by prior to this thesis have 
shown that Δ31Gαi,1 has a very similar nucleotide binding behavior compared to the full 
length Gαi,1. The reason Δ31Gαi,1 is preferred for NMR measurements is due to its smaller 
hydrodynamic radius resulting in a shorter correlation time (τC) which equals improved 
relaxation behavior. I successfully purified the labeled Δ31Gαi,1 in three different nucleotide 
states: apo, GDP-bound and GMPPNP-bound (GMPPNP was used as a more hydrolysis stable 
GTP analogue). For this work I additionally produced unlabeled NT1 bound HTGH4-L167R 
in nanodiscs as active GPCR for the studies. Along to the GPCR loaded nanodiscs I produced 
empty nanodiscs as an empty membrane reference. This resulted in nine different NMR 
samples I measured, each containing either apo, GDP-bound or GMPPNP-bound Δ31Gαi,1 
combined with either only NMR buffer, empty MSP1D1 POPC nanodiscs or MSP1D1 POPC 
nanodiscs containing NT1-bound HTGH4-L167R. The Gαi,1 NMR samples only in buffer were 
used for the backbone assignment of Δ31Gαi,1. All samples were used for the mapping of 
chemical shift perturbations and peak intensities for the different nucleotide states and for 
the presence or absence of an activated GPCR. 
Here I could show that GTP-bound Δ31Gαi,1 (or bound to GTP analogues) shows little 
dynamics due to tight binding of the nucleotide. In line with this finding I showed that 
GTP-bound Δ31Gαi,1 has little to no affinity to the activated GPCR. As GTP-bound G alpha 
subunits promote downstream signaling one would expect this finding. Additionally I could 
determine that apo and GDP-bound Δ31Gαi,1 showed a higher degree of flexibility and a more 
open conformation. These two distinct conformations led to the finding of two distinct 
populations of Δ31Gαi,1. The nucleotide state of Gαi,1 as well as the presence of NTR1 
influenced the population levels of Gαi,1. There it could be showed that Gαi,1 in its open 
conformation has a high affinity to an activated GPCR, most pronounced for the apo state of 
Gαi,1. The population of the open conformation of the GDP-bound state is stronger increased 
by the binding to the GPCR than for the apo state. In contrast to this, the closed state doesn’t 
interact with the GPCR and the closed conformation is the only present population. 
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Figure 4.1: GPCR G protein interaction 
The GPCR signaling starts with agonist binding to the GPCR. Thereby the GPCR changes its conformation and is active. GDP 
bound heterotrimeric G protein is inactive, but has an increased affinity to bind active GPCRs (1). Upon binding between the 
activated GPCR and the G protein, a conformational change in the α subunit (especially helix 5 of the Ras domain) of the 
G protein enhances the dissociation of the GDP in the nucleotide binding pocket. This apo state of the G protein has the highest 
affinity to the activated GPCR and GTP (2). As soon as GTP binds to the α subunit of the G protein, the G protein dissociates 
from the activated GPCR. The two major subunits dissociate into the α subunit and the βγ subunit. Both are responsible for 
downstream signaling and have no significant affinity to the activated GPCR (3). When the α subunit hydrolyzes the GTP to 
GDP with its intrinsic enzymatic activity, the heterotrimeric G protein can reassemble and the cycle can start again. Figure 
shown as in the original publication (Goricanec et al., 2016). 
 
In chapter 1.1 (G-Protein-coupled-receptors (GPCRs)) I showed many examples of GPCR 
structures solved in different ligand states and with various G proteins or G protein mimetics 
bound to them. But in order to get a better understanding in their activation and how they 
promote downstream signaling via G protein activation, NMR spectroscopy is big importance. 
Only via NMR spectroscopy, dynamics in the µs to ms range can be observed on an atomic 
level as well as the determination of different states being present at the same time. 
Many different methods are used in NMR spectroscopy to investigate the dynamics as well as 
the allosteric changes of GPCRs. This is either accomplished by the use of special tags i.e. the 
19F labelling of cysteines (Horst et al., 2013; Liu et al., 2012; Susac et al., 2018), by the use of 
13C methyl labelling of proteins during expression (Kofuku et al., 2014; Solt et al., 2017; 
Toyama et al., 2017; Xu et al., 2019). Even selective 15N labelling strategies (Eddy et al., 2018b; 
Isogai et al., 2016) have been applied as well as tryptophan mutagenesis for extrinsic NMR 
probes (Eddy et al., 2018a). 
In recent years, a lot of insight was gained on the receptor activation mechanisms and 
allostery (Bostock et al., 2019; Casiraghi et al., 2019; Flock et al., 2015; Shimada et al., 2019; 
Thal et al., 2018). With all this knowledge, we wanted to determine the dynamics and the 
allosteric activation of the NTR1 variants. 
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The first project involved the use of ILVA labeled NTR1 variants in different ligand states and 
with the presence or absence of a G protein. The assignments have been done prior to my 
work and will not be discussed in detail here. My part of the project was to express HTGH4 
wt, HTGH4 L167R and TM86V L167R in M9 (D2O) for ILVA labelling. After successful 
expression, all 3 variants were purified in an agonist as well as antagonist bound state. 
Thereby only for HTGH4 wt, the apo form as well as the antagonist bound receptors were 
produced. As described in the appendix, the apo as well as the 2nd antagonist state were 
omitted for further studies. This decision was made, due to the fact that the differences 
between those three ligand states were nearly non exisiting. Due to its favorable handling 
properties, SR-142948 bound NTR1 was used to study the inactive GPCR form. Additionally, 
the 2 step G protein titration step was also skipped, as the 50% G protein relative to agonist 
bound NTR1 showed nearly identical spectra as only agonist bound NTR1. Therefor only one 
G protein NTR1 complex was measured via NMR, with an excess of G protein added to the 
GPCR (see Figure A.1). All the NTR1 variants were measured in d26-DH7PC due to smaller 
micelle size compared to DDM micelles.  
As expected from previous results of the signaling activity of the NTR1 (Egloff et al., 2014), 
no significant differences between all ligand states can be observed for HTGH4 wt (see Figure 
A.2). This can be explained with the impaired signaling potency of HTGH4 wt, which is 
caused by the thermostabilizing mutation of Arginine to Leucine at position 167 (R3.50L). The 
mutation of Arginine in this class A GPCR conserved region (D/ERY) causes a not functional 
ionic lock. HTGH4 L167R shows the opposite signaling behavior. Hereby big differences 
between the agonist and antagonist bound form can be seen (see Figure A.2). Comparing these 
spectra shows chemical shifts for many peaks, with some peaks disappearing completely. The 
number of affected peaks surpasses the labeled residues in the ligand binding pocket, which 
can then only be explained by allosteric changes throughout the GPCR. Additionally, the 
spectrum of HTGH4 L167R titrated with an excess of heterotrimeric G protein is fairly 
distinct, compared to the spectra of antagonist and agonist bound forms. This could be 
explained by an interaction of the NTR1 and G protein, either with peaks being affect via 
direct interaction, as well as conformational selection of the GPCR via the G protein and 
therefor allosteric effects. The dynamics of TM86V L167R are between the two extremes of 
HTGH4 wt and HTGH4 L167R. In general it shows a similar signaling behavior like the 
HTGH4 L167R, but in a smaller extent. The differences between the agonist and antagonist 
bound state are smaller for the TM86V L167R in contrast to HTGH4 L167R, which is also the 
case if the agonist state is compared with and without G protein. This could be explained by 
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a less stable transient opening of the ionic lock, due to allosteric effects in TM86V L167R, as 
it is more NTR1 wild type like. These findings are also supported by comparing the different 
ligand states directly for each NTR1 variant (see Figure A.3). 
A second method which I used to get insight into the GPCR activation mechanism, was the 
use of 13C-MMTS as a cysteine specific methyl label. This label was already successfully used 
in NMR (Religa et al., 2011), and I had similar or even identical tagging positions compared to 
the 19F studies on β2AR (Horst et al., 2013; Liu et al., 2012). The first part of the project was to 
establish the tagging of the unlabeled GPCR. For this I adapted an already published protocol 
(Religa et al., 2011) to the NTR1 variants. Via electrospray ionization mass spectrometry (ESI-
MS, see Figure A.4) I could prove complete tagging of the GPCR. In order to track the helix 6 
movement of the GPCR, valine at position 300 (6.27 according to Ballesteros Weinstein) was 
mutated to a cysteine. With this construct I completed the assignment of all cysteines which 
could be tagged (see Figure A.8 and Figure 4.2) 
 
Figure 4.2: Structure of HTGH4 with the cysteines and leucine 167 showed as spheres (here C300 is shown as V) 
This is a cartoon representations of the crystal structure of HTGH4 (pdb: 4BWB). Inaccessible cysteines for tagging with MMTS 
are shown as blue and yellow spheres, with the former being isolated inside the helical bundle whereas the latter form a 
disulfide bridge. The orange spheres represent cysteines which have been tagged with MMTS in this work. The cysteine in 
position 300 is obtained via mutagenesis as a valine is present in the wildtype in this position. The red spheres show the position 
of the amino acid 167 in HTGH4, 3.50 in Ballesteros/Weinstein nomenclature. This is a conserved residue in class A GPCRs. In 
this figure the amino acid at 167 is a leucine (as the structures was solved for the thermostabilized HTGH4 variant), whereas in 
the wildtype this amino acid is an arginine. 
 
As we know from already published studies, TM86V L167R is in contrast to HTGH4 L167R 
switchable. The latter is active in G protein activation independent of the ligand state, 
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whereas TM86V L167R is only active while NT1 bound. I wanted to know which of the 15 
mutations difference between both NTR1 constructs is responsible for this behavior. Our 
collaboration partners at the Universität Zürich provided us with information about the 4 
most promising mutations. These 4 mutations were then cloned by myself into the HTGH4 
L167R V300C vector to obtain 4 additional single mutants, the HTGH4 L167R V300C 
A260I/R101T/D124E/E150D. 
In the next step, their thermal stability depending on the ligand and tagging state was checked 
via CD spectroscopy (see Figure A.5 until Figure A.7). All HTGH4 L167R V300C variants show 
nearly identical behavior as HTGH4 L167R. Two findings were of particular interest. First, 
TM86V variants show inverted tendencies for the stability of tagged versus untagged 
constructs if compared to HTGH4 constructs. This could be explained by the fact, that HTGH4 
is more hydrophobic close to the ionic lock than TM86V due to the evolutionary stabilization 
process. Therefor a methyl tagged cysteine would stabilize this region even further, whereas 
this effect is opposite in the less hydrophobic region for TM86V. Second, for each ligand state 
as well as tagging state, the R101T variant shows an increased stability. The exact details for 
this mechanism still have to be studied, which could be done via the ILVA experiments giving 
insight in the allosteric network. 
I recorded 1H-13C methyl-TROSY NMR for each NTR1 variant in an agonist bound (NT1) 
active state as well as in an antagonist bound (SR-142948) inactive state. Except for C386, all 
labeled cysteines showed two peaks, each representing either the active or the inactive state. 
As the cysteine at position 386 did not change for any NTR1 variant or ligand state, it was 
used as a reference in all spectra. All spectra and their peak height analysis are shown in the 
Appendix (Figure A.9 until Figure A.15). For a better visual comparison of all spectra, their 
peak heights can be seen in Figure A.16. In this comparison it can be seen that HTGH4 L167R 
V300C D124E as well as TM86V L167R V300C show the most populated ground states in the 
agonist bound state. In contrast to this, HTGH4 L167R V300C E150D shows the most 
populated active states in the agonist bound state. The relative populations of the other 
observed NTR1 variants are somewhere between those two extremes. For the antagonist 
bound state, similar results are obtained. The most populated active state is detected for the 
NT1 bound state of HTGH4 L167R V300C E150D. The HTGH4 L167R V300C D124E variant 
shows the least populated active states in the antagonist bound form. A general tendency is 
that the other NTR1 variants vary more in the antagonist bound state compared to the agonist 
bound form. To get a better understanding of these results, further experiments are necessary. 
One possibility would be to create multiple mutations for one construct in order to investigate 
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their collaborative effects. Another direction for the investigation of key residues in signaling 
is a titration with heterotrimeric G protein and its effect on the population of the different 
states. Lastly, I want to mention, that ideally all experiments should be repeated without the 
presence of detergent, preferably in a native like environment like phospholipid nanodiscs. 
An important aspect in studying the structural biology of membrane proteins, is the use of 
membrane mimetics. Even though detergents are easy to handle, they can alter the function 
of membrane proteins. Therefor the use of native-like membrane mimetics is the preferred 
choice. Recently the use of phospholipid nanodiscs got more and more popular. Their use in 
biochemistry exists for nearly two decades (Bayburt et al., 2002; Bayburt and Sligar, 2010), 
only recently their application in structural biology increased. One of the reasons was their 
optimization for structural biology via different sizes (Hagn et al., 2013; Hagn et al., 2018). As 
the MSP used for the nanodiscs was linear and not covalently bound, their thermal stability 
as well as their size homogeneity varied. A solved structure of nanodiscs via NMR (Bibow et 
al., 2017) could explain these problems. Therefor methods to overcome this problem were 
desired. One method to optimize the stability and size homogeneity is the use of covalently 
circularized nanodiscs. There were already methods available to produce covalently 
circularized nanodiscs in vitro (Nasr et al., 2017), but they were difficult to produce and it was 
a time-consuming process. The aim of this project was an easy and fast method, preferably in 
vivo, to produce circularized membrane scaffold protein (cMSP) of different sizes for a 
covalently circularized nanodisc preparation. 
The first step in this project the cloning of the cMSP constructs Thereby I designed a PCR 
strategy to clone the Nostoc punctiforme DnaE split-inteins before and after the MSP sequence 
(see Figure 4.3). Following the successful cloning of the cMSP plasmids, I established the first 
protein production and purification steps with my intern Jonas Miehling. Following this 
ground laying work, Jonas Miehling continued and finished the project completely by himself 
(Miehling et al., 2018). 
In this work we showed via electron microscopy, that the circularized nanodiscs have a better 
size homogeneity. They also had a higher thermal stability as determined via CD thermal 
melting curves. Both effects help to obtain better spectra in NMR as well as in cryo EM. As 
model membrane proteins to confirm the improved properties of circularized nanodiscs, 
bacterial outer membrane protein X (OmpX) and human voltage-dependent anion channel 
subtype 1 (VDAC1) have been used. In both cases better spectra could be obtained in 
circularized than linear MSP derived nanodiscs. With VDAC1 containing nanodiscs it could 
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also be seen that higher measurement temperatures for NMR are possible, what also enabled 
better spectral quality. 
 
 
Figure 4.3: cMSP split intein splicing 
Here, the molecular mechanism of split intein mediated MSP circularization is shown. Split inteins are cloned around linear 
MSP constructs. During expression, both split inteins align together and catalyze the circularization.  
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A. Appendix 
The dynamics of the thermostabilized NTR1 were investigated in the second half of the PhD 
thesis as it was outlined in the aims of the thesis (see 1.31.3 “Aims of the Thesis”). Therefor 
the data acquired and analyzed for this part of the project is unpublished to date. Certain 
experiments still have to be done in the lab to get a better understanding on the dynamics of 
the NTR1 with the underlying mechanisms of GPCR activation and G protein interaction. 
a. Unpublished Data 
GPCR allostery mapped with ILVA labeled NTR1 variants 
The main goal of this project is to get a deeper understanding of the allosteric network of 
NTR1 activation. In this context the influence of the thermostabilizing mutations on this 
process should be investigated. Therefore, 3 different NTR1 variants were used for the 
analysis: 
 HTGH4 “wt” (L167) 
 HTGH4 L167R 
 TM86V L167R 
We were also interested in the influence of the ligand state on the activation mechanism. In 
this regard we checked the following ligand states: 
 Apo 
 SR-48692: Non-peptide antagonist. It is selective for the neurotensin receptors, but not 
selective between subtypes (Gully et al., 1993) 
 SR-142948: Non-peptide antagonist. It is selective for the neurotensin receptors, but 
not selective between subtypes (Nalivaiko et al., 1998) 
 NT1: Truncated NT1 peptide containing the amino acid positions 8 to 13 with an N-
terminal glycine linker and 3C cleavage rest: GPGGRRPYIL 
As the apo state and both antagonists showed similar behavior in NMR, only SR-142948 was 
used in further studies to obtain the inactive NTR1 state. This antagonist was also solely used 
in the 2nd project of unpublished results. 
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Lastly the effect of unlabeled heterotrimeric G protein, obtained from insect cells by our 
collaboration partners in Harvard Medical School (Prof. Gerhard Wagner and Meng Zhang), 
on the NT1 activated NTR1 variants was analyzed. First two different concentrations of the 
G protein relative to the GPCR were used, a 1:2 ratio of G protein to GPCR and a 2:1 ratio of 
G protein relative to GPCR. As both showed identical behavior in NMR, the rest of the 
experiments were titrated with a 3:2 ratio of G protein to GPCR. 
As the NTR1 variants were analyzed via NMR spectroscopy, it first had to be assigned. This 
has already been done before my involvement in this project by Prof. Franz Hagn and 
Prof. Joshua Ziarek (now Indiana University Bloomington) during their time at the Harvard 
Medical School (Prof. Gerhard Wagner). The assignments for the 1H-13C methyl groups from 
the ILVA labeling are nearly complete, whereas the 1H-15N assignments are incomplete 
(approximately 30% of all possible signals). This can be explained by the protein production. 
As the GPCR is directly folded and inserted into the membrane during expression in D2O 
containing M9 medium, all backbone amides are deuterated. During purification in aqueous 
solution, only the accessible amide deuterons are back exchanged to protons. All deuterons 
of the backbone amides in the transmembrane region cannot exchange with the protons. 
My part of the project was to express the NTR1 variants in M9 (D2O) ILVA medium, to purify 
the GPCRs in the different ligand states and to measure the NMR spectra for analysis. The 
labeled expression was done as described in chapter 2.1.4 (Isotope labeling Strategies). 
Following the expression, the NTR1 variants were purified as explained in chapter 2.1.1 
(Neurotensin Receptor 1 (NTR1)). After successful purification, the samples were 
concentrated to the maximum and as described in chapter 2.4 (NMR Spectroscopy) prepared 
for NMR measurement. For each sample a [1H-15N] 2D TROSY and an optimized [1H-13C] 2D 
HMQC also called methyl-TROSY (Tugarinov et al., 2003) was recorded. The results are 
shown in Figure A.1 until Figure A.3.  
In Figure A.1 six different [1H-13C] HMQC spectra of ILVA labeled HTGH4 wt in different 
ligand states and titrated with heterotrimeric G protein are overlayed. I am missing the 
assignments, therefor the spectra are analyzed in a qualitative manner. Three different peak 
regions are zoomed in as examples of changes in the spectra. The zoomed in region on top 
shows different peak shifts and intensities for all 6 variants. The middle zoomed in region 
shows no changes between the 6 different ligand states. The bottom one shows only peaks 
for the agonist bound state, but not for the apo or antagonist bound states. As the differences 
in the antagonist and apo spectra were neglectable and the yield of apo form NTR1 was really 
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low, only one spectrum was recorded for the inactive form of NTR1 in future experiments. 
The antagonist chosen for the studies was SR-142948. Additionally, only titrations with excess 
of heterotrimeric G protein were performed for the other NTR1 variants, as the 50% G protein 
spectrum was identical to the spectrum only with agonist bound to HTGH4 wt.  
Figure A.2 shows the overlays of [1H-13C] HMQC spectra of ILVA labeled NTR1 variants for 
each investigated NTR1 variant. Thereby the SR-142948 bound NTR1 variants are shown in 
black, the NT1 bound NTR1 variants in red and the NT1 bound NTR1 variants titrated with 
an excess of G protein in blue. The NTR1 variants of this study are HTGH4 wt (left overlay), 
HTGH4 L167R (middle overlay) and TM86V L167R (right overlay). It can be seen that in the 
case of HTGH4 wt no differences are significantly visible for all three ligand and titration 
states. This is in line with the impaired signaling potency of HTGH4 wt due to the Leucine at 
position 167, leading to an impaired ionic lock. In line with these results, HTGH4 L167R shows 
the exact opposite effects. The differences between the antagonist bound form and the agonist 
bound form are very big. For many peaks a chemical shift can be observed, as well as peaks 
disappearing completely. This means that many residues are affected by the different ligands 
and therefor an allosteric effect is a plausible cause as only a small fraction of labeled residues 
is present in the ligand binding pocket. The spectrum with the titrated heterotrimeric G 
protein is also very distinct to the other two ligand states, as some peaks are only visible for 
one of both spectra. This could be explained by a strong interaction between the NTR1 and 
the G protein. In the case of TM86V L167R, similar observations can be made, but to a lower 
extent. The differences in the spectra for the antagonist as well as the agonist bound state are 
smaller compared to HTGH4 L167R, as well as the differences in the spectra for the agonist 
bound state with and without heterotrimeric G protein. A more transient activation of the 
“wild type” like TM86V L167R compared to HTGH4 L167R would be an explanation of this 
effect. 
The overlays of [1H-13C] HMQC spectra of ILVA labeled NTR1 variants for each ligand state 
shown in Figure A.3 Thereby the HTGH4 wt spectra are shown in black, the HTGH4 L167R 
spectra in red and the TM86V L167R spectra in blue. The spectra of the SR-142948 bound 
NTR1 variants used in his study are overlaid on the left, The NT1 bound NTR1 variants of 
this study are overlaid in the middle and the NT1 bound NTR1 variants of this study titrated 
with heterotrimeric G protein are overlaid on the right. These results further underline the 
findings explained by Figure A.2. The differences between the spectra for the SR-142948 
bound NTR1 forms are relatively big and each variant shows a distinct pattern. In contrast to 
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this, the NT1 bound states, both L167R variants are very similar, with only HTGH4 wt being 
significantly different. 
 
ILVA labeled NTR1 in DH7PC  ILVA labeled NTR1 in DH7PC  
HTGH4 wt apo Blue HTGH4 wt NT1 Yellow 
HTGH4 wt SR-142948 Red HTGH4 wt NT1 +50% G protein Pink 
HTGH4 wt SR-48692 Green HTGH4 wt NT1 +200% G protein Black 
 
Figure A.1: [1H-13C] HMQC of ILVA labeled HTGH4 wt in different ligand states and titrated with heterotrimeric G protein 
This figure shows the overlay of 6 different [1H-13C] HMQC spectra. Each spectrum represents ILVA labeled HTGH4 wt with 
different ligand conditions as described on top of the spectra. As the data is not complete so far, the spectra are analyzed in a 
qualitative manner. 3 Peaks are shown as examples of changes in the spectra (zoomed in). The top one shows different peak 
shifts and intensities for all 6 variants. The middle peak shows no changes between the 6 different ligand states. The bottom one 
shows only peaks for the agonist bound state, but not for the apo or antagonist bound states. 
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Figure A.2: Overlays of [1H-13C] HMQC spectra of ILVA labeled NTR1 variants for each NTR1 variant 
For each overlay the black spectrum represents the SR142948 bound NTR1 variant, the red spectrum represents the NT1 bound 
NTR1 variant and the blue spectrum represents the NT1 bound NTR1 variant in complex with excess heterotrimeric G protein. 
The overlay of NMR spectra on the left is showing the different ligand states of HTGH4 wt. The overlay of NMR spectra in the 
middle is showing the different ligand states of HTGH4 L167R. The overlay of NMR spectra on the right is showing the different 
ligand states of TM86V L167R. 
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Figure A.3: Overlays of [1H-13C] HMQC spectra of ILVA labeled NTR1 variants for each ligand state 
For each overlay the black spectrum represents HTGH4 wt, the red spectrum represents HTGH4 L167R and the blue spectrum 
represents TM86V. The overlay of NMR spectra on the left is showing the different NTR1 variants in the SR142948 bound state. 
The overlay of NMR spectra in the middle is showing the different NTR1 variants in the NT1 bound state. The overlay of NMR 
spectra on the right is showing the different NTR1 variants in the NT1 bound state in complex with excess of heterotrimeric 
G protein. 
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GPCR activation mapped with 13C-MTS labeled NTR1 variants 
The main goal of this project is to get a deeper understanding of the NTR1 activation. In this 
context the influence of the thermostabilizing mutations on the GPCR signaling was analyzed. 
As for the ILVA study, 3 different NTR1 variants were used for the analysis, but they all had 
an additional cysteine cloned in order to probe for helix 6 movement (V300C, 6.27 according 
to Ballesteros-Weinstein): 
 HTGH4 “wt” (L167) V300C 
 HTGH4 L167R V300C 
 TM86V L167R V300C 
In order to assign the cysteines which could be tagged with the 13C-MMTS reagent, an 
additional variant was cloned:  
 HTGH4 L167R C386S 
I also wanted to get further insight in which mutations from the TM86V to the HTGH4 variant 
have an influence on the GPCR signaling. With the help of unpublished data from our 
collaboration partners at the University of Zürich (Prof. Andreas Plückthun), we also used 
four different mutants which they identified as strongly involved in the activation process: 
 HTGH4 L167R V300C A260I 
 HTGH4 L167R V300C R101T 
 HTGH4 L167R V300C D124E 
 HTGH4 L167R V300C E150D 
In this project, I was also interested in the influence of the ligand state on the activation 
mechanism. In this regard we checked the following ligand states: 
 SR-142948 
 NT1 
The reasoning behind only using SR-142948 to obtain the inactive NTR1 state has been 
explained in the previously shown unpublished results. 
Expression and purification of the unlabeled NTR1 variants was done according to our 
adapted NTR1 purification protocol described in chapter 2.1.1 (Neurotensin Receptor 1 
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(NTR1)). After successful purification, the samples were concentrated to the maximum and as 
described in chapter 2.4 (NMR Spectroscopy) prepared for NMR measurement. For each 
sample a [1H-13C] 2D HMQC also called methyl-TROSY (Tugarinov et al., 2003) was recorded. 
As the NTR1 variants needed to be tagged with 13C-MMTS, I adapted and optimized the 
tagging procedure to our system as explained in chapter 2.1.4 (Isotope labeling Strategies). To 
verify the tagging efficiency determined by NMR spectroscopy, electrospray ionization mass 
spectrometry (ESI-MS) was used (see Figure A.4). Here the molecular weight difference of an 
exemplary NTR1 variant (HTGH4 L167R V300C) is determined, with being either tagged 
(37617 Da) or not tagged (37425 Da). For all HTGH4 variants with the V300C mutation the 
weight difference is 192 Da. As each tag has a molecular weight of 48 Da (S13CH3), 4 cysteines 
are accessible for tagging in HTGH4 V300C variants and therefor complete tagging was 
proven (4 tags à 48 Da equals 192 Da). 
To obtain all the needed mutants of NTR1 described earlier, I used the QuikChange Lightning 
Site-Directed Mutagenesis Kit from Agilent according to the manufacturers instruction 
manual (see Appendix b: Material). 
Additionally, I measured CD spectra and thermal denaturation curves of the newly generated 
NTR1 mutants to verify their structural integrity as well as to estimate their thermal stability 
(see Figure A.5 until Figure A.7). Four thermal melting curves were recorded for each analyzed 
NTR1 mutant. The four different CD measurements have been done with and without tag as 
well as in a NT1 and SR142948 bound state. In all CD melting curves, the dashed lines 
represent the tagged constructs, whereas the solid lines show the untagged constructs. These 
experiments show that tagged constructs are on average more stable than their untagged 
counterparts and they show also that TM86V variants are less stable than the HTGH4 
variants. In order to simplify the analysis of the CD melting curves, only tagged or untagged 
NT1 bound NTR1 variants were compared in one figure (see Figure A.6), whereas their 
SR-142948 bound counterparts were compared in another figure (see Figure A.7). The CD data 
show that for the HTGH4 variants, the tagged constructs are more stable than the untagged 
counterparts. In contrast to this the TM86V variant which is tagged is less stable than the 
untagged one. For NT1 bound HTGH4 constructs all untagged variants have a similar melting 
point except for the R101T variant, having an increased stability. Antagonist bound HTGH4 
constructs show the same behavior with an increased stability also for the A260I variant. 
In order to be able to analyze the NTR1 variants via NMR spectroscopy, I first had to assign 
all accessible cysteines that could be tagged. Thereby I first measured the 13C-methyl tagged 
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NTR1 variants HTGH4 wt and HTGH4 L167R which show the same residues being tagged, 
C172, C386 and C388. As the cysteines in helix 8 (386 and 388) are in a similar chemical 
environment, I mutated the cysteine at position 386 to serine and tagged this NTR1 variant, 
resulting in a loss of one of the two similar peaks. This enabled me to obtain all 3 residues 
being assigned. In the next step I used the 13C-methyl tagged HTGH4 L167R and compared it 
to 13C-methyl tagged HTGH4 L167R V300C to get the assignment of the cysteine at position 
300 (V300C6.27). Due to the fact, that the TM86V has one cysteine more than the HTGH4, I 
compared the 13C-methyl tagged TM86V L167R V300C to the 13C-methyl tagged HTGH4 
L167R V300C. This gave me the final assignment needed, for the TM86V specific cysteine 332 
(see Figure A.8). 
With the assignments for the 1H-13C methyl groups from the 13C-MMTS tagging now 
obtained, I measured a methyl-TROSY NMR for each NTR1 variant. Thereby each variant was 
also measured in an agonist bound (NT1) active state as well as in an antagonist bound 
(SR-142948) inactive state. For all labeled cysteines, two peaks were visible, each representing 
one state. In my nomenclature I used the asterisk to denominate the peak corresponding to 
the presumed active state. The cysteine at position 386 did not change for any NTR1 variant 
or ligand state and was there for used as a reference, i.e. for the analysis of the peak heights. 
It is also the only cysteine without a corresponding peak for the presumed active state. In 
order to visualize the populations for each peak, I also display the relative peak height for 
each pair of inactive and active state peaks. The resulting spectra and their peak height 
analysis are shown in Figure A.9 to Figure A.15. A comparison of all spectra can be seen in 
Figure A.16. 
There by a comparison of all investigated NTR1 variants respective to their peak height is 
shown. The top graph is a comparison of agonist bound NTR1 variants, whereas the bottom 
graph is a comparison of antagonist bound NTR1 variants. All peak heights are normalized 
relative to C386 (therefor C386 = 1.00). The top graph shows that HTGH4 L167R V300C D124E 
as well as TM86V L167R V300C show the most populated ground states in the agonist bound 
state. Opposite to these tendencies, HTGH4 L167R V300C E150D shows the most populated 
active states in the agonist bound state. The other observed NTR1 variants are found between 
those two extremes. For the antagonist bound state, similar results are obtained. The most 
populated active state is detected for the NT1 bound state of HTGH4 L167R V300C E150D. 
The HTGH4 L167R V300C D124E variant shows the least populated active states in the 
antagonist bound form. A general tendency is that the other NTR1 variants vary more in the 
antagonist bound state compared to the agonist bound form.  
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Figure A.4: Exemplary ESI-MS to verify NTR1 tagging 
This is an exemplary ESI-MS data set, which have been used to verify complete MMTS tagging of the NTR1 variants. The 
molecular weight difference of the NTR1 variant (HTGH4 L167R V300C) which is tagged (37617 Da) and the one which is not 
tagged (37425 Da) is 192 Da. Each tag has a molecular weight of 48 Da (S13CH3). As 4 cysteines are accessible for tagging, 
complete tagging was proven (4 tags à 48 Da equals 192 Da) 
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Figure A.5: CD thermal melting curves of all the HTGH4 L167R V300C back mutation variants in DDM 
All thermal melting curves recorded via CD spectroscopy of all newly generated NTR1 variants for the MMTS tagging are 
shown in this overlay. For each construct, 4 thermal melting curves were recorded, with and without tag as well as in NT1 and 
SR142948 bound state. The dashed lines show the tagged constructs, whereas the solid lines show the untagged constructs. Two 
observations can be directly made: tagged constructs are on average more stable than the untagged counterparts and the TM86V 
variants are less stable than the HTGH4 variants 
 
Table A.1. List of melting termperatures obtained via CD spectroscopy 
NTR1 Variant 
NT1 
+ 13C MTS 
SR142948 
+ 13C MTS 
NT1 SR142948 
HTGH4 L167R V300C 78 °C 79 °C n/a n/a 
HTGH4 L167R V300C D124E 77 °C 74 °C 73 °C 70 °C 
HTGH4 L167R V300C E150D 77 °C 74 °C 74 °C 72 °C 
HTGH4 L167R V300C R101T 81 °C 81 °C 78 °C 77 °C 
HTGH4 L167R V300C A260I 79 °C 79 °C 72 °C 77 °C 
TM86V L167R 68 °C 68 °C 71 °C 69 °C 
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Figure A.6: CD thermal melting curves of the HTGH4 L167R V300C back mutation variants bound to NT1 in DDM 
The thermal melting curves recorded via CD spectroscopy of NT1 bound NTR1 variants for the MMTS tagging are here overlaid. 
To simplify the analysis of the melting curves from Figure A.5, only 2 thermal melting curves are shown per construct: with and 
without tag. The dashed lines show the tagged constructs, whereas the solid lines show the untagged constructs. For the HTGH4 
variants, the tagged constructs are on more stable than the untagged counterparts. In the case of TM86V the tagged variant is 
less stable than the untagged one. All untagged variants have a similar melting point except for the R101T variant, which 
shows increased stability. For this construct the tagged version is the most stable, too. 
 
 
Figure A.7: CD thermal melting curves of the HTGH4 L167R V300C back mutation variants bound to SR-142948 in DDM 
The thermal melting curves recorded via CD spectroscopy of SR142948 bound NTR1 variants for the MMTS tagging are here 
overlaid. To simplify the analysis of the melting curves from Figure A.5, only 2 thermal melting curves are shown per construct: 
with and without tag. The dashed lines show the tagged constructs, whereas the solid lines show the untagged constructs. For 
the HTGH4 variants, the tagged constructs are on more stable than the untagged counterparts. In the case of TM86V the tagged 
variant is less stable than the untagged one. All untagged variants have a similar melting point except for the R101T and the 
A260I variant, which show increased stability. For both of these constructs the tagged version is also more stable. 
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Figure A.8: 13C-MMTS assignment spectra 
These are the spectra which were used to assign all cysteines which could be tagged. On the left side, an overlay of HTGH4 
L167R V300C (black) and HTGH4 L167R C386S (red) is shown. The peaks are always centered according to the reference 
spectrum in black. Peaks which are labeled with an asterisk correspond to an active conformation, whereas the ones without 
correspond to the ground state (assignment of inactive ground state peaks was done with the HTGH4 wt peaks (see Figure A.9)) 
as HTGH4 wt shows no signaling activity at all. It can be seen that 2 peaks are missing in the red spectrum as the V300C 
mutation is not present in this NTR1 variant and additionally the C386 is mutated to serine. For the C386, in all spectra only 
one peak is present, showing that it is completely unaffected by the conformational state of the NTR1. Therefor it is used as 
reference peak in all spectra. On the right side, TM86V L167R V300C (black) and TM86V L167R (red) are overlaid. With this 
experiment, the assignment of the 300C could be confirmed. Additionally, the C332 could be assigned, as this cysteine is only 
present in TM86V but not in HTGH4.  
 
 
 
Figure A.9: 13C-MMTS tagged HTGH4 wt V300C 
These are the spectra comparing HTGH4 wt V300C with different ligands. On the left side, an overlay of HTGH4 wt V300C NT1 
(black) and HTGH4 wt V300C SR-142948 (red) is shown. The peaks are labeled as explained in Figure A.8. It can be seen that 
both spectra are identical in their peak shifts as well as peak heights. On the right side, the peak heights of the spectra shown in 
the left are displayed as bar diagram. They are normalized relative to C386 (therefor C386 = 1.00). Both graphical 
representations show that only ground state is present and that the populations are independent on the ligand state of this NTR1 
variant. 
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Figure A.10: 13C-MMTS tagged HTGH4 L167R V300C 
These are the spectra comparing HTGH4 L167R V300C with different ligands. On the left side, an overlay of HTGH4 L167R 
V300C NT1 (black) and HTGH4 L167R V300C SR-142948 (red) is shown. The peaks are labeled as explained in Figure A.8. It can 
be seen that both spectra have different peak heights for all peaks except the constant C386 peak. On the right side, the peak 
heights of the spectra shown in the left are displayed as bar diagram. They are normalized relative to C386 (therefor C386 = 
1.00). Both graphical representations show that in the antagonist bound state the ground state peaks are more pronounced than 
the active state peaks. If the HTGH4 L167R V300C is bound to the agonist NT1, the populations are populated inverse to the 
antagonist bound state, with the active state being more populated. 
 
 
Figure A.11: 13C-MMTS tagged TM86V L167R V300C 
These are the spectra comparing TM86V L167R V300C with different ligands. On the left side, an overlay of TM86V L167R 
V300C NT1 (black) and TM86V L167R V300C SR-142948 (red) is shown. The peaks are labeled as explained in Figure A.8. It can 
be seen that both spectra have different peak heights for all peaks except the constant C386 peak. On the right side, the peak 
heights of the spectra shown in the left are displayed as bar diagram. They are normalized relative to C386 (therefor C386 = 
1.00). In contrast to the HTGH4 L167R V300C variants (Figure A.10), the differences are not as strongly pronounced in the 
populations. Still both graphical representations show that in the antagonist bound state the ground state peaks are more 
pronounced than the active state peaks. If the TM86V L167R V300C is bound to the agonist NT1, the populations are populated 
inverse to the antagonist bound state, with the active state being more populated. The peak corresponding to C388 as well as the 
TM86V specific peak corresponding to C332 are not affected by the different ligands. 
 
 
65 
 
Figure A.12: 13C-MMTS tagged HTGH4 L167R V300C A260I 
These are the spectra comparing HTGH4 L167R V300C A260I with different ligands. On the left side, an overlay of HTGH4 
L167R V300C A260I NT1 (black) and HTGH4 L167R V300C A260I SR-142948 (red) is shown. The peaks are labeled as explained 
in Figure A.8. It can be seen that both spectra have different peak heights for all peaks except the constant C386 peak. On the 
right side, the peak heights of the spectra shown in the left are displayed as bar diagram. They are normalized relative to C386 
(therefor C386 = 1.00). Both graphical representations show that in the antagonist bound state the ground state peaks are more 
pronounced than the active state peaks. If the HTGH4 L167R V300C A260I is bound to the agonist NT1, the populations are 
populated inverse to the antagonist bound state, with the active state being more populated. 
 
 
Figure A.13: 13C-MMTS tagged HTGH4 L167R V300C R101T 
These are the spectra comparing HTGH4 L167R V300C R101T with different ligands. On the left side, an overlay of HTGH4 
L167R V300C R101T NT1 (black) and HTGH4 L167R V300C R101T SR-142948 (red) is shown. The peaks are labeled as explained 
in Figure A.8. It can be seen that both spectra have different peak heights for all peaks except the constant C386 peak. On the 
right side, the peak heights of the spectra shown in the left are displayed as bar diagram. They are normalized relative to C386 
(therefor C386 = 1.00). Both graphical representations show that in the antagonist bound state the ground state peaks are more 
pronounced than the active state peaks. If the HTGH4 L167R V300C R101T is bound to the agonist NT1, the populations are 
populated inverse to the antagonist bound state, with the active state being more populated. 
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Figure A.14: 13C-MMTS tagged HTGH4 L167R V300C E150D 
These are the spectra comparing HTGH4 L167R V300C E150D with different ligands. On the left side, an overlay of HTGH4 
L167R V300C E150D NT1 (black) and HTGH4 L167R V300C E150D SR-142948 (red) is shown. The peaks are labeled as explained 
in Figure A.8. It can be seen that both spectra have different peak heights for all peaks except the constant C386 peak. On the 
right side, the peak heights of the spectra shown in the left are displayed as bar diagram. They are normalized relative to C386 
(therefor C386 = 1.00). Both graphical representations show that in the antagonist bound state the ground state peaks are more 
pronounced than the active state peaks. If the HTGH4 L167R V300C E150D is bound to the agonist NT1, the populations are 
populated inverse to the antagonist bound state, with the active state being more populated. 
 
 
Figure A.15: 13C-MMTS tagged HTGH4 L167R V300C D124E 
These are the spectra comparing HTGH4 L167R V300C D124E with different ligands. On the left side, an overlay of HTGH4 
L167R V300C D124E NT1 (black) and HTGH4 L167R V300C D124E SR-142948 (red) is shown. The peaks are labeled as explained 
in Figure A.8. It can be seen that both spectra have different peak heights for all peaks except the constant C386 peak. On the 
right side, the peak heights of the spectra shown in the left are displayed as bar diagram. They are normalized relative to C386 
(therefor C386 = 1.00). Both graphical representations show that in the antagonist bound state the ground state peaks are more 
pronounced than the active state peaks. If the HTGH4 L167R V300C D124E is bound to the agonist NT1, the populations are 
populated inverse to the antagonist bound state, with the active state being more populated. 
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Figure A.16: Comparison 13C-MMTS tagged NTR1 variant peak heights 
In this figure we see the comparison of all investigated NTR1 variants respective to their peak height. The top graph is a 
comparison of agonist bound NTR1 variants, whereas the bottom graph is a comparison of antagonist bound NTR1 variants. 
The peaks are labeled as explained in Figure A.8. They are normalized relative to C386 (therefor C386 = 1.00). The top graph 
shows that HTGH4 L167R V300C D124E as well as TM86V L167R V300C show the most populated ground states in the agonist 
bound state. In contrast to this, HTGH4 L167R V300C E150D shows the most populated active states in the agonist bound state. 
The other NTR1 variants are between those two extremes. A comparable tendency can also be observed in the antagonist bound 
state. HTGH4 L167R V300C E150D is like in the NT1 bound state the one with the biggest population of the active state. And 
also the HTGH4 L167R V300C D124E variant shows the least populated active states in the antagonist bound form. But the other 
NTR1 variants vary more in the antagonist bound state compared to the agonist bound form. 
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b. Material 
Reagent Manufacturer 
L-Alanine-3-13C, 2-d Sigma-Aldrich 
Ammonium-15N chloride Sigma-Aldrich 
CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate) 
Sigma-Aldrich 
Cholesteryl hemisuccinate Sigma-Aldrich 
Deuterium chloride solution Sigma-Aldrich 
DM (n-Decyl-β-D-Maltopyranoside) Cube Biotech 
d26-DH7PC (1,2-Diheptanoyl-sn-glycero-3-phosphocholine) FB Reagents 
DDM (n-Dodecyl β-D-maltoside) Cube Biotech 
D-Glucose-1,2,3,4,5,6,6-d7 Sigma-Aldrich 
2-Keto-3-(methyl-d3)-butyric acid-4-13C FB Reagents 
2-Ketobutyric acid-4-13C,3-d FB Reagents 
13C-MMTS (S-Methyl-13C methanethiosulfonate) Sigma-Aldrich 
NEB® Express Iq Competent E. coli (High Efficiency) NEB 
NHS-Activated Sepharose 4 Fast Flow GE Healthcare 
QuikChange Lightning Site-Directed Mutagenesis Kit, 10 Rxn Agilent 
Sodium deuteroxide solution Sigma-Aldrich 
SR 142948 Tocris 
SR 48692 Sigma-Aldrich 
Succinic acid-2,2,3,3-d4 Sigma-Aldrich 
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CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CHS Cholesteryl hemisuccinate 
cMSP Circularized membrane scaffold protein 
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cryo-EM Cryo electron microscopy 
DDM n-Dodecyl β-D-maltoside 
DEER Double electron-electron resonance 
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DM n-Decyl β-D-maltoside 
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ND Nanodisc 
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OmpX Bacterial outer membrane protein X 
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POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
RD Relaxation dispersion 
RDC Residual dipolar coupling 
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SP Sulphopropyl 
T4L T4 lysozyme 
τc Correlation time 
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TM Transmembrane 
TROSY Transverse relaxation-optimized spectroscopy 
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